<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="c6eb7560-fd61-427f-bead-bf8ccefdb33d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">
         <content styleCode="bold">
            <content styleCode="bold">These highlights do not include all the information needed to use LEVOFLOXACIN safely and effectively. See full prescribing information for LEVOFLOXACIN. <br/>
            </content>
            <content styleCode="bold">LEVOFLOXACIN Injection in 5% DEXTROSE, solution for intravenous use<br/>
            </content>
            <content styleCode="bold">Initial U.S. Approval: 1996</content>
         </content>
      </content>
   </title>
   <effectiveTime value="20160816"/>
   <setId root="e680c759-16c5-4532-9c9c-f42c8c3df74a"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="001230762" root="1.3.6.1.4.1.519.1"/>
            <name>West-Ward Pharmaceuticals Corp</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="452742943" root="1.3.6.1.4.1.519.1"/>
                        <name>HIKMA FARMACEUTICA (PORTUGAL), S.A</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9722" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9721" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9720" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9722" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9721" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9720" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9722" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9721" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9720" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9722" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9721" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0143-9720" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2c62477e-b1f5-48ad-8d9f-27088a985fb7"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL LISTING DATA ELEMENTS SECTION"/>
               <effectiveTime value="20160921"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0143-9722" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levofloxacin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levofloxacin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="mL" value="50"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6GNT3Y5LMF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOFLOXACIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RIX4E89Y14" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOFLOXACIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2500"/>
                              <denominator unit="mL" value="50"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0143-9722-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="24"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0143-9722-24" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20110916"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091375" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110916"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0143-9721" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levofloxacin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levofloxacin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6GNT3Y5LMF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOFLOXACIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RIX4E89Y14" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOFLOXACIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="5000"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0143-9721-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="24"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0143-9721-24" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20110916"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091375" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110916"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0143-9720" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Levofloxacin</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Levofloxacin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="750"/>
                              <denominator unit="mL" value="150"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6GNT3Y5LMF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOFLOXACIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RIX4E89Y14" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOFLOXACIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="7500"/>
                              <denominator unit="mL" value="150"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="150"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0143-9720-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="24"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0143-9720-24" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20110916"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091375" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110916"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_a8e87156-1790-4479-b994-930898fd7c9e">
               <id root="12f59056-6932-4820-89ac-5c62da6f3884"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="xmChange">- Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (</content>
                        <content styleCode="xmChange">
                           <linkHtml href="#LINK_0991ea01-74a1-403b-851a-36a06ec4872e">5.1</linkHtml>
                        </content>
                        <content styleCode="xmChange">)], including:</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Circle">
                     <item>
                        <content styleCode="bold">
                           <content styleCode="xmChange">Tendinitis and tendon rupture [see Warnings and Precautions (</content>
                           <content styleCode="xmChange">
                              <linkHtml href="#LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">5.2</linkHtml>
                           </content>
                           <content styleCode="xmChange">)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="xmChange">Peripheral neuropathy [see Warnings and Precautions (</content>
                           <content styleCode="xmChange">
                              <linkHtml href="#LINK_7a390283-f0a5-4bf0-9f4a-be9c29fd2fcb">5.3</linkHtml>
                           </content>
                           <content styleCode="xmChange">)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="xmChange">Central nervous system effects [see Warnings and Precautions (</content>
                           <content styleCode="xmChange">
                              <linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>
                           </content>
                           <content styleCode="xmChange">)]</content>
                        </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="xmChange">Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (</content>
                        <content styleCode="xmChange">
                           <linkHtml href="#LINK_0991ea01-74a1-403b-851a-36a06ec4872e">5.1</linkHtml>
                        </content>
                        <content styleCode="xmChange">)]</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="xmChange">- Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis [see Warnings and Precautions (</content>
                        <content styleCode="xmChange">
                           <linkHtml href="#LINK_aaee3dd2-757e-45de-815b-91e5d8b415e6">5.5</linkHtml>
                        </content>
                        <content styleCode="xmChange">)].</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="xmChange">- Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (</content>
                        <content styleCode="xmChange">
                           <linkHtml href="#LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">5.1-5.14</linkHtml>
                        </content>
                        <content styleCode="xmChange">)], reserve levofloxacin for use in patients who have no alternative treatment options for the following indications:</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Circle">
                     <item>
                        <content styleCode="bold">
                           <content styleCode="xmChange">Uncomplicated urinary tract infection [see Indications and Usage (</content>
                           <content styleCode="xmChange">
                              <linkHtml href="#LINK_681c4997-2c01-4b8a-81cb-03b1e4e47da2">1.12</linkHtml>
                           </content>
                           <content styleCode="xmChange">)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="xmChange">Acute bacterial exacerbation of chronic bronchitis [see Indications and Usage (</content>
                           <content styleCode="xmChange">
                              <linkHtml href="#LINK_c6c7d68d-c7d3-4be1-94e6-45436f186678">1.13</linkHtml>
                           </content>
                           <content styleCode="xmChange">)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="bold">
                           <content styleCode="bold">
                              <content styleCode="xmChange">Acute bacterial sinusitis [see Indications and Usage (</content>
                              <content styleCode="xmChange">
                                 <linkHtml href="#LINK_0d91e8dc-a950-4bdd-92b8-b2629df2dbb3">1.14</linkHtml>
                              </content>
                              <content styleCode="xmChange">)]</content>
                           </content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20160816"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: </content>
                           <content styleCode="bold">SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="bold">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold">Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together (<linkHtml href="#LINK_0991ea01-74a1-403b-851a-36a06ec4872e">5.1</linkHtml>), including:</content>
                              <list listType="unordered" styleCode="Circle">
                                 <item>
                                    <content styleCode="bold">Tendinitis and tendon rupture (<linkHtml href="#LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">5.2</linkHtml>)</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Peripheral neuropathy (<linkHtml href="#LINK_7a390283-f0a5-4bf0-9f4a-be9c29fd2fcb">5.3</linkHtml>)</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Central nervous system effects (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>) </content>
                                 </item>
                              </list>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions (<linkHtml href="#LINK_0991ea01-74a1-403b-851a-36a06ec4872e">5.1</linkHtml>).</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis [see Warnings and Precautions (<linkHtml href="#LINK_aaee3dd2-757e-45de-815b-91e5d8b415e6">5.5</linkHtml>)].</content>
                           </item>
                           <item>
                              <content styleCode="bold">Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions (<linkHtml href="#LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">5.1-5.14</linkHtml>), reserve levofloxacin for use in </content>
                              <content styleCode="bold">patients who have no alternative treatment options for the following indications: </content>
                              <list listType="unordered" styleCode="Circle">
                                 <item>
                                    <content styleCode="bold">Uncomplicated urinary tract infection (<linkHtml href="#LINK_681c4997-2c01-4b8a-81cb-03b1e4e47da2">1.12</linkHtml>) </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Acute bacterial exacerbation of chronic bronchitis (<linkHtml href="#LINK_c6c7d68d-c7d3-4be1-94e6-45436f186678">1.13</linkHtml>)</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Acute bacterial sinusitis (<linkHtml href="#LINK_0d91e8dc-a950-4bdd-92b8-b2629df2dbb3">1.14</linkHtml>)</content>
                                 </item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_083a9c46-8f52-40d6-9379-16967a1d9ddc">
               <id root="573217c5-9790-47a0-8a5d-2279e2b05530"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20160815"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <linkHtml href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">Boxed Warning</linkHtml>                              06/2016</paragraph>
                        <paragraph>Indications and Usage (<linkHtml href="#LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">1</linkHtml>)             06/2016</paragraph>
                        <paragraph>Dosage and Administration (<linkHtml href="#LINK_85590813-5e0e-4242-a548-b5a0b528e548">2</linkHtml>)      06/2016</paragraph>
                        <paragraph>Warnings and Precautions (<linkHtml href="#LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">5</linkHtml>)       06/2016</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">
               <id root="fcf71ebd-0334-4f46-976c-958f87551a59"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Levofloxacin injection is indicated for the treatment of adults (≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Levofloxacin injection is indicated when intravenous administration offers a route of administration advantageous to the patient (e.g., patient cannot tolerate an oral dosage form).</paragraph>
               </text>
               <effectiveTime value="20160816"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥ 18 years of age) with infections caused by designated, susceptible bacteria (<linkHtml href="#LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">1</linkHtml>, <linkHtml href="#LINK_ed3d8a3b-5eb5-4634-9172-3959fba7ebda">12.4</linkHtml>).</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Pneumonia: nosocomial (<linkHtml href="#LINK_ec57cf8b-c6c6-447f-af86-bc68f3f7fbe7">1.1</linkHtml>) and community acquired (<linkHtml href="#LINK_0d0471b5-b25b-4e6d-940c-5e341a4bef4a">1.2</linkHtml>, <linkHtml href="#LINK_651eafeb-cbc1-4e66-add1-cb0d8d16fc14">1.3</linkHtml>) 



</item>
                           <item>Skin and skin structure infections: complicated (<linkHtml href="#LINK_e61644b5-b3b1-49d8-a1ee-cbc913b2203f">1.4</linkHtml>) and uncomplicated (<linkHtml href="#LINK_68a329b8-50a0-4fa4-84ed-afd0b7cbfe3e">1.5</linkHtml>)</item>
                           <item>Chronic bacterial prostatitis (<linkHtml href="#LINK_3e7b8675-31aa-4bb3-ab45-4e7f1e835ce0">1.6</linkHtml>) </item>
                           <item>Inhalational anthrax, post-exposure (<linkHtml href="#LINK_8eacae28-b314-4a45-9357-42bea6ffb8d8">1.7</linkHtml>) </item>
                           <item>Plague (<linkHtml href="#LINK_5f968ece-0395-425c-90a2-175b5911e7a8">1.8</linkHtml>)</item>
                           <item>Urinary tract infections: complicated (<linkHtml href="#LINK_0b2c03e7-e8ac-4b75-9c7e-383686d9b26b">1.9</linkHtml>, <linkHtml href="#LINK_bf9ca393-6490-47de-8d91-adfb7d13002a">1.10</linkHtml>) and uncomplicated (<linkHtml href="#LINK_681c4997-2c01-4b8a-81cb-03b1e4e47da2">1.12</linkHtml>) </item>
                           <item>Acute pyelonephritis (<linkHtml href="#LINK_0e2f16a6-0ea9-4dff-8efb-27cb1d9b40c2">1.11</linkHtml>) </item>
                           <item>Acute bacterial exacerbation of chronic bronchitis (<linkHtml href="#LINK_c6c7d68d-c7d3-4be1-94e6-45436f186678">1.13</linkHtml>)</item>
                           <item>Acute bacterial sinusitis (<linkHtml href="#LINK_0d91e8dc-a950-4bdd-92b8-b2629df2dbb3">1.14</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_ec57cf8b-c6c6-447f-af86-bc68f3f7fbe7">
                     <id root="43af8b7d-cd1c-42d6-851a-257435e8882c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.1 Nosocomial Pneumonia</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin-susceptible <content styleCode="italics">Staphylococcus aureus</content>, <content styleCode="italics">Pseudomonas aeruginosa</content>, <content styleCode="italics">Serratia marcescens</content>, <content styleCode="italics">Escherichia coli</content>, <content styleCode="italics">Klebsiella pneumoniae</content>, <content styleCode="italics">Haemophilus influenzae</content>, or <content styleCode="italics">Streptococcus pneumoniae</content>. Adjunctive therapy should be used as clinically indicated. Where <content styleCode="italics">Pseudomonas aeruginosa</content> is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_20b92eae-b505-4e25-a012-6b7ea12bab25">14.1</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160505"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0d0471b5-b25b-4e6d-940c-5e341a4bef4a">
                     <id root="bf7e7821-9a37-4483-b748-58ee5bea4ff5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible<content styleCode="italics"> Staphylococcus aureus, Streptococcus pneumoniae</content> (including multi-drug-resistant <content styleCode="italics">Streptococcus pneumoniae</content> [MDRSP]), <content styleCode="italics">Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, </content>or<content styleCode="italics"> Mycoplasma pneumoniae </content>[see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">2.1</linkHtml>) </content>and <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_7bfbeeef-706d-4728-951a-d82fe51742c1">14.2</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥ 2 mcg/mL), 2<sup>nd</sup> generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_651eafeb-cbc1-4e66-add1-cb0d8d16fc14">
                     <id root="4079353d-2a83-41cc-9ecc-08d4b172da47"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of community-acquired pneumonia due to<content styleCode="italics"> Streptococcus pneumoniae</content> (excluding multi-drug-resistant isolates [MDRSP]), <content styleCode="italics">Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, </content>or<content styleCode="italics"> Chlamydophila pneumoniae </content>[see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">2.1</linkHtml>); CLINICAL STUDIES (<linkHtml href="#LINK_d37e1bfb-e002-4c81-883d-58e722a52a65">14.3</linkHtml>)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20141007"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e61644b5-b3b1-49d8-a1ee-cbc913b2203f">
                     <id root="2c295ec3-3d82-44e5-8d5d-af9426728169"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">

1.4 Complicated Skin and Skin Structure Infections</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin‑susceptible <content styleCode="italics">Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, </content>or<content styleCode="italics"> Proteus mirabilis </content>[see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_edad6655-a3a5-44f1-8cdd-6b7dd03e58cb">14.5</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_68a329b8-50a0-4fa4-84ed-afd0b7cbfe3e">
                     <id root="f078805c-6c97-480f-9d75-0630422784d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">

1.5 Uncomplicated Skin and Skin Structure Infections</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible<content styleCode="italics"> Staphylococcus aureus</content>, or <content styleCode="italics">Streptococcus pyogenes</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3e7b8675-31aa-4bb3-ab45-4e7f1e835ce0">
                     <id root="04367ef7-1957-4712-89a4-41e1378c7220"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">

1.6 Chronic Bacterial Prostatitis</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to <content styleCode="italics">Escherichia coli, Enterococcus faecalis, </content>or methicillin-susceptible<content styleCode="italics"> Staphylococcus epidermidis </content>[see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_16b0995a-829f-4052-8d18-ca2c6c7e96aa">14.6</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8eacae28-b314-4a45-9357-42bea6ffb8d8">
                     <id root="7b1fda56-7060-4633-9355-8caf99d2ce2a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">

1.7 Inhalational Anthrax (Post-Exposure)</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized <content styleCode="italics">Bacillus anthracis. </content>The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">2.1</linkHtml>, <linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>); </content>
                           <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5f968ece-0395-425c-90a2-175b5911e7a8">
                     <id root="733905b2-aab0-4e3a-9b55-33226c5d5dd6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">

1.8 Plague</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to <content styleCode="italics">Yersinia pestis</content> (<content styleCode="italics">Y. pestis</content>) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">2.1</linkHtml>, <linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>)</content> and <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_61466cb7-0624-4e2a-8190-17b69bbd3bfb">14.10</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0b2c03e7-e8ac-4b75-9c7e-383686d9b26b">
                     <id root="85ee36a9-b337-4ba3-8494-5ae4b5f7dbcd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of complicated urinary tract infections due to <content styleCode="italics">Escherichia coli, Klebsiella pneumoniae, </content>or <content styleCode="italics">Proteus mirabilis </content>[see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_2ef23ab7-6006-481b-8fc4-08bca9b2655c">14.7</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_bf9ca393-6490-47de-8d91-adfb7d13002a">
                     <id root="c0893cce-ec71-4d5c-b945-cf303e56e875"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to <content styleCode="italics">Enterococcus faecalis</content>, <content styleCode="italics">Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,</content> or <content styleCode="italics">Pseudomonas aeruginosa </content>[see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_f00de8b2-e8fa-4e23-aaa7-36a8a642f8fb">14.8</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0e2f16a6-0ea9-4dff-8efb-27cb1d9b40c2">
                     <id root="b8a773de-38f6-4b4a-96e2-bcdf4872acb9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of acute pyelonephritis caused by <content styleCode="italics">Escherichia coli</content>, including cases with concurrent bacteremia [see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_2ef23ab7-6006-481b-8fc4-08bca9b2655c">14.7</linkHtml>, <linkHtml href="#LINK_f00de8b2-e8fa-4e23-aaa7-36a8a642f8fb">14.8</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_681c4997-2c01-4b8a-81cb-03b1e4e47da2">
                     <id root="238a41c8-3ebc-4b20-8159-88ce8895e465"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.12 Uncomplicated Urinary Tract Infections</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to <content styleCode="italics">Escherichia coli, Klebsiella pneumoniae, </content>or<content styleCode="italics"> Staphylococcus saprophyticus</content>.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">5.1-5.14</linkHtml>)</content>] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c6c7d68d-c7d3-4be1-94e6-45436f186678">
                     <id root="77b2dbcc-60cf-4b27-8f76-525ca70c674f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.13 Acute Bacterial Exacerbation of Chronic
Bronchitis</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin‑susceptible <content styleCode="italics">Staphylococcus aureus</content>, <content styleCode="italics">Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, </content>or <content styleCode="italics">Moraxella catarrhalis</content>.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">5.1-5.14</linkHtml>)</content>]and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0d91e8dc-a950-4bdd-92b8-b2629df2dbb3">
                     <id root="24f3be2b-22aa-4b82-80f4-701e926317ad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">

1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day
Treatment Regimens</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated for the treatment of acute bacterial sinusitis (ABS) due to <content styleCode="italics">Streptococcus pneumoniae</content>, <content styleCode="italics">Haemophilus influenzae, </content>or<content styleCode="italics"> Moraxella catarrhalis </content>[see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_48f57bf0-9a7c-4dd5-b0da-db93a6a42881">14.4</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">5.1-5.14</linkHtml>)</content>] and for some patients ABS is self-limiting, reserve levofloxacin for treatment of ABS in patients who have no alternative treatment options.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a7b84a38-d1da-4248-8f0b-6cc263a3ba3e">
                     <id root="19ce1ed1-bb5f-4283-8e47-41e9159fb200"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.15 Usage</content>
                     </title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Culture and susceptibility testing<br/>
                           </content>Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see <content styleCode="bold">MICROBIOLOGY (<linkHtml href="#LINK_ed3d8a3b-5eb5-4634-9172-3959fba7ebda">12.4</linkHtml>)</content>]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.</paragraph>
                        <paragraph>As with other drugs in this class, some isolates of <content styleCode="italics">Pseudomonas aeruginosa</content> may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_85590813-5e0e-4242-a548-b5a0b528e548">
               <id root="3d13dab8-1bb8-4610-bed9-90162c116ef7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20160816"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item> Dosage in patients with normal renal function (<linkHtml href="#LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">2.1)</linkHtml> </item>
                        </list>
                        <table>
                           <col width="155.95pt"/>
                           <col width="49.6pt"/>
                           <col width="49.6pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Type of Infection </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Dose Every<br/>
                                       </content>
                                       <content styleCode="bold">24 hours</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Duration<br/>
                                       </content>
                                       <content styleCode="bold">(days)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Nosocomial Pneumonia (<linkHtml href="#LINK_ec57cf8b-c6c6-447f-af86-bc68f3f7fbe7">1.1</linkHtml>) </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>750 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>7-14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Community Acquired Pneumonia (<linkHtml href="#LINK_0d0471b5-b25b-4e6d-940c-5e341a4bef4a">1.2</linkHtml>) </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>7-14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Community Acquired Pneumonia (<linkHtml href="#LINK_651eafeb-cbc1-4e66-add1-cb0d8d16fc14">1.3</linkHtml>) </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>750 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Complicated Skin and Skin Structure Infections (SSSI) (<linkHtml href="#LINK_e61644b5-b3b1-49d8-a1ee-cbc913b2203f">1.4</linkHtml>)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>750 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>7-14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">Uncomplicated SSSI (<linkHtml href="#LINK_68a329b8-50a0-4fa4-84ed-afd0b7cbfe3e">1.5</linkHtml>)</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">500 mg </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">7-10 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">Chronic Bacterial Prostatitis (<linkHtml href="#LINK_3e7b8675-31aa-4bb3-ab45-4e7f1e835ce0">1.6</linkHtml>)</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">500 mg</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">28 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Toprule         Lrule          Rrule     " valign="top">Inhalational Anthrax (Post-Exposure) (<linkHtml href="#LINK_8eacae28-b314-4a45-9357-42bea6ffb8d8">1.7</linkHtml>)</td>
                                 <td align="center" styleCode="     Toprule         Lrule          Rrule     " valign="top"> </td>
                                 <td align="center" styleCode="     Toprule         Lrule          Rrule     " valign="top"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule         Lrule          Rrule     " valign="top">
                                    <paragraph>Adults and Pediatric Patients &gt; 50 kg</paragraph>
                                    <paragraph>Pediatric Patients &lt; 50 kg and ≥ 6 months of age</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg</paragraph>
                                    <paragraph>8 mg/kg BID (not to exceed 250 mg/dose)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">
                                    <paragraph>60</paragraph>
                                    <paragraph>60</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Toprule         Lrule          Rrule     " valign="top">Plague (<linkHtml href="#LINK_5f968ece-0395-425c-90a2-175b5911e7a8">1.8</linkHtml>)</td>
                                 <td align="center" styleCode="     Toprule         Lrule          Rrule     " valign="top"> </td>
                                 <td align="center" styleCode="     Toprule         Lrule          Rrule     " valign="top"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule         Lrule          Rrule     " valign="top">
                                    <paragraph>Adults and Pediatric Patients &gt; 50 kg</paragraph>
                                    <paragraph>Pediatric Patients &lt; 50 kg and ≥ 6 months of age</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg</paragraph>
                                    <paragraph>8 mg/kg BID (not to exceed 250 mg/dose)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">
                                    <paragraph>10 to 14</paragraph>
                                    <paragraph>10 to 14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule         Lrule          Rrule     " valign="top">Complicated Urinary Tract Infection (<linkHtml href="#LINK_0b2c03e7-e8ac-4b75-9c7e-383686d9b26b">1.9</linkHtml>) or Acute Pyelonephritis (<linkHtml href="#LINK_0e2f16a6-0ea9-4dff-8efb-27cb1d9b40c2">1.11</linkHtml>)</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">750 mg</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule         Lrule          Rrule     " valign="top">Complicated Urinary Tract Infection (<linkHtml href="#LINK_bf9ca393-6490-47de-8d91-adfb7d13002a">1.10</linkHtml>) or Acute Pyelonephritis (<linkHtml href="#LINK_0e2f16a6-0ea9-4dff-8efb-27cb1d9b40c2">1.11</linkHtml>)</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">250 mg</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">10</td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule         Lrule          Rrule     " valign="top">Uncomplicated Urinary Tract Infection (<linkHtml href="#LINK_681c4997-2c01-4b8a-81cb-03b1e4e47da2">1.12</linkHtml>)</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">250 mg</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule         Lrule          Rrule     " valign="top">Acute Bacterial Exacerbation of Chronic Bronchitis (<linkHtml href="#LINK_c6c7d68d-c7d3-4be1-94e6-45436f186678">1.13</linkHtml>)</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">500 mg</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">7</td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="     Botrule         Lrule          Rrule     " valign="top">Acute Bacterial Sinusitis (<linkHtml href="#LINK_0d91e8dc-a950-4bdd-92b8-b2629df2dbb3">1.14</linkHtml>)</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">750 mg</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">5</td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">500 mg</td>
                                 <td align="center" styleCode="     Botrule         Lrule          Rrule     " valign="top">10-14</td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered" styleCode="Disk">
                           <item>Adjust dose for creatinine clearance &lt; 50 mL/min (<linkHtml href="#LINK_c56b5e0e-be06-4991-9c8f-e3fb91021240">2.3</linkHtml>, <linkHtml href="#LINK_7e047670-63c8-4b2f-9dda-d2261568eaa3">8.6</linkHtml>, <linkHtml href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</linkHtml>) </item>
                           <item>IV Injection, Premix: Slow IV infusion only, over 60 or 90 minutes depending on dose. Avoid rapid or bolus IV (<linkHtml href="#LINK_c66ccf10-2cdb-4177-a8c1-87592e9d2b62">2.5</linkHtml>) </item>
                           <item>Do not mix with other medications in IV line (<linkHtml href="#LINK_03cd1151-5874-4992-91b2-e26387b8c6da">2.6</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">
                     <id root="993d85b5-073d-46b3-bdee-c7b260f9a8aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Dosage in Adult Patients with Normal Renal Function</content>
                     </title>
                     <text>
                        <paragraph>The usual dose of levofloxacin injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours, as indicated by infection and described in <content styleCode="bold">Table 1</content>.</paragraph>
                        <paragraph>These recommendations apply to patients with creatinine clearance ≥ 50 mL/min. For patients with creatinine clearance &lt; 50 mL/min, adjustments to the dosing regimen are required [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_c56b5e0e-be06-4991-9c8f-e3fb91021240">2.3</linkHtml>)</content>].</paragraph>
                        <table>
                           <caption>Table 1: Dosage in Adult Patients with Normal Renal Function (creatinine clearance ≥ 50 mL/min)</caption>
                           <col width="11cm"/>
                           <col width="4cm"/>
                           <col width="2cm"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Type of Infection<sup>1</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Dosed Every 24 hours</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Duration<br/>(days)<sup>2</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Nosocomial Pneumonia</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>750 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7–14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Community Acquired Pneumonia<sup>3</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7–14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Community Acquired Pneumonia<sup>4</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>750 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Complicated Skin and Skin Structure Infections (SSSI)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>750 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7–14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Uncomplicated SSSI</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7–10</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Chronic Bacterial Prostatitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>28</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Inhalational Anthrax (Post-Exposure), adult and pediatric patients &gt; 50 kg<sup> 7,8</sup>
                                       <br/>Pediatric patients &lt; 50 kg and ≥ 6 months of age <sup>7,8</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg<br/>see <content styleCode="bold">Table 2</content> below (<linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>60 <sup>8</sup>
                                       <br/>60 <sup>8</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Plague, adult and pediatric patients &gt; 50 kg<sup> 9</sup>
                                       <br/>Pediatric patients &lt; 50 kg and ≥ 6 months of age</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph> 500 mg<br/>see <content styleCode="bold">Table 2 </content>below (<linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">10 to 14<br/>10 to 14</td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)5</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">750 mg</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">5</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)6</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">250 mg</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">10</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">Uncomplicated Urinary Tract Infection</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">250 mg</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">500 mg</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">7</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <content styleCode="xmChange">Acute Bacterial Sinusitis (ABS)</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">750 mg</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">5</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">500 mg </content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="xmChange">10-14</content> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>1</sup> Due to the designated pathogens [see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">1</linkHtml>)</content>]. <br/>
                           <sup>2</sup> Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician. <br/>
                           <sup>3</sup> Due to methicillin-susceptible<content styleCode="italics"> Staphylococcus aureus, Streptococcus pneumoniae</content> (including multi-drug-resistant isolates [MDRSP]), <content styleCode="italics">Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, </content>or <content styleCode="italics">Mycoplasma pneumoniae </content>[see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_0d0471b5-b25b-4e6d-940c-5e341a4bef4a">1.2</linkHtml>)</content>].<br/>
                           <sup>4</sup> Due to<content styleCode="italics"> Streptococcus pneumoniae</content> (excluding multi-drug-resistant isolates [MDRSP]), <content styleCode="italics">Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae </content>[see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_651eafeb-cbc1-4e66-add1-cb0d8d16fc14">1.3</linkHtml>)</content>]. <br/>
                           <sup>5</sup> This regimen is indicated for cUTI due to <content styleCode="italics">Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis </content>and AP due to <content styleCode="italics">E. coli,</content> including cases with concurrent bacteremia. <br/>
                           <sup>6</sup> This regimen is indicated for cUTI due to<content styleCode="italics"> Enterococcus faecalis, Enterococcus cloacae, Escherichia coli</content>, <content styleCode="italics">Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa</content>; and for AP due to<content styleCode="italics"> E. coli.<br/>
                           </content>
                           <sup>7</sup> Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized <content styleCode="italics">B. anthracis</content>. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>)</content>]. <br/>
                           <sup>8</sup> The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.10</linkHtml>)</content>; <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</linkHtml>); </content>and <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>)</content>] Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk.<br/>
                           <sup>9</sup> Drug administration should begin as soon as possible after suspected or confirmed exposure to <content styleCode="italics">Yersinia pestis</content>. Higher doses of levofloxacin typically used for treatment of pneumonia can be used for treatment of plague, if clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">
                     <id root="081d80e9-47bd-4b00-baed-51e582a22ee2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Dosage in Pediatric Patients</content>
                     </title>
                     <text>
                        <paragraph>The dosage in pediatric patients ≥ 6 months of age is described below in <content styleCode="bold">Table 2</content>.</paragraph>
                        <table>
                           <caption>Table 2: Dosage in Pediatric Patients ≥ 6 months of age</caption>
                           <col width="212.65pt"/>
                           <col width="191.35pt"/>
                           <col width="3cm"/>
                           <col width="49.6pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Type of Infection <sup>1</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Dose</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Freq. Once Every</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Duration<sup>2</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">Inhalational Anthrax (post-exposure)<sup>3,4</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Pediatric patients &gt; 50 kg</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>24 hr</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>60 days<sup>4</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Pediatric patients &lt; 50 kg and ≥ 6 months of age</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>8 mg/kg (not to exceed 250 mg per dose)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>12 hr</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>60 days<sup>4</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">Plague<sup>5</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">Pediatric patients &gt; 50 kg</td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">500 mg </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> 24 hr</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> 10 to 14 days</td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">Pediatric patients &lt; 50 kg and ≥ 6 months of age</td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">8 mg/kg (not to exceed 250 mg per dose)</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> 12 hr</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> 10 to 14 days</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>1</sup> Due to <content styleCode="italics">Bacillus anthracis </content>[see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_c6c7d68d-c7d3-4be1-94e6-45436f186678">1.13</linkHtml>)</content>] and <content styleCode="italics">Yersinia pestis</content> [(see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_0d91e8dc-a950-4bdd-92b8-b2629df2dbb3">1.14</linkHtml>)</content>] <br/>
                           <sup>2</sup> Sequential therapy (intravenous to oral) may be instituted at the discretion of the physician. <br/>
                           <sup>3</sup> Drug administration should begin as soon as possible after suspected or confirmed exposure to aerosolized <content styleCode="italics">B. anthracis</content>. This indication is based on a surrogate endpoint. Levofloxacin plasma concentrations achieved in humans are reasonably likely to predict clinical benefit [see <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>)</content>] <br/>
                           <sup>4</sup> The safety of levofloxacin in pediatric patients for durations of therapy beyond 14 days has not been studied. An increased incidence of musculoskeletal adverse events compared to controls has been observed in pediatric patients [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.10</linkHtml>)</content>; <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</linkHtml>)</content>; <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>)</content>.] Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk.<br/>
                           <sup>5</sup> Drug administration should begin as soon as possible after suspected or confirmed exposure to <content styleCode="italics">Yersinia pestis</content>.</paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c56b5e0e-be06-4991-9c8f-e3fb91021240">
                     <id root="e500f047-1275-4b7f-ab26-7d1586ff03a8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Dosage Adjustment in Adults with Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>Administer levofloxacin with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.</paragraph>
                        <paragraph>No adjustment is necessary for patients with a creatinine clearance ≥ 50 mL/min.</paragraph>
                        <paragraph>In patients with impaired renal function (creatinine clearance &lt; 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [see <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_7e047670-63c8-4b2f-9dda-d2261568eaa3">8.6</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 3 </content>shows how to adjust dose based on creatinine clearance.</paragraph>
                        <table>
                           <caption>Table 3: Dosage Adjustment in Adult Patients with Renal Impairment (creatinine clearance &lt; 50 mL/min)</caption>
                           <col width="148.85pt"/>
                           <col width="99.25pt"/>
                           <col width="127.55pt"/>
                           <col width="163pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Dosage in Normal Renal Function<br/>Every 24 hours</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Creatinine Clearance<br/>20 to 49 mL/min</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Creatinine Clearance<br/>10 to 19 mL/min</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Hemodialysis or Chronic Ambulatory Peritoneal Dialysis (CAPD)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>750 mg</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>750 mg every 48 hours</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>750 mg initial dose, then 500 mg every 48 hours</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>750 mg initial dose, then 500 mg every 48 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg initial dose, then 250 mg every 24 hours</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg initial dose, then 250 mg every 48 hours</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>500 mg initial dose, then 250 mg every 48 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>250 mg</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>No dosage adjustment required</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>250 mg every 48 hours. If treating uncomplicated UTI, then no dosage adjustment is required</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>No information on dosing adjustment is available</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7a7eb258-b154-4fd3-b0de-94f5ef07cf24">
                     <id root="2904b3e5-f474-4be5-bc40-015ac55ec8c0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.4 Drug Interaction with Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Levofloxacin Injection<br/>
                           </content>Levofloxacin Injection should not be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_03cd1151-5874-4992-91b2-e26387b8c6da">2.6</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c66ccf10-2cdb-4177-a8c1-87592e9d2b62">
                     <id root="c6015af4-ed5f-4b82-92cc-0d8549070ead"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.5 Administration Instructions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Levofloxacin Injection <br/>
                           </content>Caution: Rapid or bolus intravenous infusion of levofloxacin has been associated with hypotension and must be avoided. Levofloxacin injection should be infused intravenously slowly over a period of not less than 60 or 90 minutes, depending on the dosage. Levofloxacin injection should be administered only by intravenous infusion. It is not for intramuscular, intrathecal, intraperitoneal, or subcutaneous administration.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Hydration for Patients Receiving Levofloxacin Injection <br/>
                           </content>Adequate hydration of patients receiving intravenous levofloxacin should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_38344cce-d4d7-4566-8a4a-28ff594d1902">6.1</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_758ffc71-e10b-4ebd-a010-25ce6bbd7f8d">17.2</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_03cd1151-5874-4992-91b2-e26387b8c6da">
                     <id root="b8da869c-fd14-4ab9-b2cc-5b821000deda"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.6 Preparation of Intravenous Product</content>
                     </title>
                     <text>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                        <paragraph>Because only limited data are available on the compatibility of levofloxacin injection with other intravenous substances, additives or other medications should not be added to Levofloxacin Injection Premix in Single Dose Flexible Containers, or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of levofloxacin injection with an infusion solution compatible with levofloxacin injection and with any other drug(s) administered via this common line.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Levofloxacin Injection Premix in Single Dose Flexible Containers (5 mg/mL)<br/>
                           </content>Levofloxacin injection is supplied in flexible containers within a foil overwrap. These contain a premixed, ready to use levofloxacin solution in 5% dextrose (D5W) for single dose. The 50 mL premixed flexible containers contain 250 mg/50 mL, the 100 mL premixed flexible containers contain 500 mg/100 mL, and the 200 mL premixed flexible containers contain 750 mg/150 mL of levofloxacin solution. The concentration of each container is 5 mg/mL. No further dilution of these preparations is necessary. Because the premix flexible containers are for single dose only, any unused portion should be discarded.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Instructions for the Use of Levofloxacin Injection Premix in Flexible Containers</content>:</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Tear outer wrap at the notch and remove solution container.  

</item>
                           <item>Check the container for minute leaks by squeezing the inner bag firmly. If leaks are found, or if the seal is not intact, discard the solution, as the sterility may be compromised. 

</item>
                           <item>Do not use if the solution is cloudy or a precipitate is present. 

</item>
                           <item>Use sterile equipment. 

</item>
                           <item>
                              <content styleCode="bold">WARNING: Do not use flexible containers in series connections.</content> Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete. </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Preparation for Administration</content>:</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Close flow control clamp of administration set. </item>
                           <item>Remove cover from port at bottom of container. </item>
                           <item>Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. <content styleCode="bold">NOTE: See full directions on administration set carton.</content>
                           </item>
                           <item>Suspend container from hanger. </item>
                           <item>Squeeze and release drip chamber to establish proper fluid level in chamber during infusion of Levofloxacin Injection Premix in Flexible Containers. </item>
                           <item>Open flow control clamp to expel air from set. Close clamp. </item>
                           <item>Regulate rate of administration with flow control clamp. </item>
                        </list>
                     </text>
                     <effectiveTime value="20141007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_453db056-8e5b-4a49-b3b1-e8b4f8ebef3d">
               <id root="d6f743b2-53d5-4a69-8742-dc5e7587119a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph> INJECTION (5 mg/mL in 5% Dextrose) Premix in Single Dose Flexible Containers, for intravenous infusion</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>50 mL container, fill volume 50 mL (equivalent to 250 mg levofloxacin) </item>
                     <item>100 mL container, fill volume 100 mL (equivalent to 500 mg levofloxacin) </item>
                     <item>200 mL container, fill volume 150 mL (equivalent to 750 mg levofloxacin) </item>
                  </list>
               </text>
               <effectiveTime value="20141007"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Formulation (<linkHtml href="#LINK_453db056-8e5b-4a49-b3b1-e8b4f8ebef3d">3</linkHtml>) </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Strength </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Injection: premix single dose flexible containers</paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>250 mg in 50 mL<br/>500 mg in 100 mL<br/>750 mg in 150 mL </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">
               <id root="d6de5a85-69d0-43af-9633-8aad4c71aa2b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Levofloxacin is contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.3</linkHtml>)</content>].</paragraph>
               </text>
               <effectiveTime value="20160815"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Known hypersensitivity to levofloxacin or other quinolones (<linkHtml href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</linkHtml>, <linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_f73e3b6b-e858-46c7-96ed-1edbbce99943">
               <id root="c81193b0-3684-4393-956f-0a028baf81ab"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20160816"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose (<linkHtml href="#LINK_ee48c310-f899-46d5-8513-3f5b635aa4f4">4</linkHtml>, <linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>) </item>
                           <item>Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>) </item>
                           <item>Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported. Discontinue immediately if signs and symptoms of hepatitis occur (<linkHtml href="#LINK_d5113ac6-9819-4e88-9a70-e37a6d8636ae">5.8</linkHtml>) </item>
                           <item>
                              <content styleCode="italics">Clostridium difficile</content>-associated colitis: evaluate if diarrhea occurs (<linkHtml href="#LINK_d2d413d2-2be2-4526-b1a0-06a3e2f20fea">5.9</linkHtml>) </item>
                           <item>Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval (<linkHtml href="#LINK_829decb8-4312-4a6c-9665-e116246457b1">5.10</linkHtml>, <linkHtml href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_0991ea01-74a1-403b-851a-36a06ec4872e">
                     <id root="339bd680-4787-48c7-8feb-fb50b9c1017f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1
Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis
and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion). These reactions can occur within hours to weeks after starting levofloxacin. Patients of any age or without pre-existing risk factors have experienced these adverse reactions [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">5.2</linkHtml>, <linkHtml href="#LINK_7a390283-f0a5-4bf0-9f4a-be9c29fd2fcb">5.3</linkHtml>, <linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Discontinue levofloxacin immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including levofloxacin, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">
                     <id root="90f3d72b-ba79-4507-9db3-bbba513ebf1a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Tendinitis and Tendon Rupture</content>
                     </title>
                     <text>
                        <paragraph>Fluoroquinolones, including levofloxacin, have been associated with an increased risk of tendinitis and tendon rupture in all ages [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_0991ea01-74a1-403b-851a-36a06ec4872e">5.1</linkHtml>) </content>and<content styleCode="bold"> ADVERSE REACTIONS (<linkHtml href="#LINK_71d889d7-4aa5-4a9e-be77-c35b07f024d4">6.2</linkHtml>)</content>]. This adverse reaction most frequently involves the Achilles tendon and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites. Tendinitis or tendon rupture can occur within hours or days of starting levofloxacin or as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally.</paragraph>
                        <paragraph> The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. Other factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have been reported in patients taking fluoroquinolones who do not have the above risk factors. Discontinue levofloxacin immediately if the patient experiences pain, swelling, inflammation or rupture of a tendon. Patients should be advised to rest at the first sign of tendinitis or tendon rupture, and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug. Avoid levofloxacin in patients who have a history of tendon disorders or tendon rupture [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_bdbfd5b5-5f2a-4f7b-a066-c2a95c73d8d9">6.3</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7a390283-f0a5-4bf0-9f4a-be9c29fd2fcb">
                     <id root="5a6b68de-ad8f-4dee-944d-ba8d413c11a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3 Peripheral Neuropathy</content>
                     </title>
                     <text>
                        <paragraph>Fluoroquinolones, including levofloxacin, have been associated with an increased risk of peripheral neuropathy. Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including levofloxacin. Symptoms may occur soon after initiation of levofloxacin and may be irreversible in some patients [see <content styleCode="bold">Warnings and Precautions (<linkHtml href="#LINK_0991ea01-74a1-403b-851a-36a06ec4872e">5.1</linkHtml>) </content>and<content styleCode="bold"> Adverse Reactions (<linkHtml href="#LINK_38344cce-d4d7-4566-8a4a-28ff594d1902">6.1</linkHtml>, <linkHtml href="#LINK_71d889d7-4aa5-4a9e-be77-c35b07f024d4">6.2</linkHtml>)</content>]. </paragraph>
                        <paragraph>Discontinue levofloxacin immediately if the patient experiences symptoms of neuropathy including pain, burning, tingling, numbness, and/or weakness or other alterations of sensation including light touch, pain, temperature, position sense, and vibratory sensation. Avoid fluoroquinolones, including levofloxacin, in patients who have previously experienced peripheral neuropathy [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_da68872a-681b-4f73-8c30-8e6138e65875">
                     <id root="d14ac80b-45c8-4a65-99df-fbf72559c15e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4 Central Nervous System Effects</content>
                     </title>
                     <text>
                        <paragraph>Fluoroquinolones, including levofloxacin, have been associated with an increased risk of central nervous system (CNS) effects, including convulsions, toxic psychoses, increased intracranial pressure (including pseudotumor cerebri). Fluoroquinolones may also cause central nervous system stimulation which may lead to tremors, restlessness, anxiety, lightheadedness, confusion, hallucinations, paranoia, depression, nightmares, insomnia, and, rarely, suicidal thoughts or acts. These reactions may occur following the first dose. If these reactions occur in patients receiving levofloxacin, discontinue levofloxacin and institute appropriate measures. As with other fluoroquinolones, levofloxacin should be used with caution in patients with a known or suspected central nervous system (CNS) disorder that may predispose them to seizures or lower the seizure threshold (e.g., severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors that may predispose them to seizures or lower the seizure threshold (e.g., certain drug therapy, renal dysfunction). [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</linkHtml>)</content>; <content styleCode="bold">DRUG INTERACTIONS (<linkHtml href="#LINK_30a94422-889f-4ef0-b3fa-2be80926bc8f">7.4</linkHtml>, <linkHtml href="#LINK_c22078fc-57b5-4b7c-9f61-efec69ff90f4">7.5</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_aaee3dd2-757e-45de-815b-91e5d8b415e6">
                     <id root="d9bd12a0-844c-4643-aac6-4fbf479651d6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 Exacerbation of Myasthenia Gravis</content>
                     </title>
                     <text>
                        <paragraph>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_bdbfd5b5-5f2a-4f7b-a066-c2a95c73d8d9">6.3</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_288e647e-d314-4849-9e55-18178c949b0d">
                     <id root="3b10e1bc-6d55-481a-9543-9a932d20cf3f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.6 Other Serious and Sometimes Fatal Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>Other serious and sometimes fatal adverse reactions, some due to hypersensitivity, and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including levofloxacin. These events may be severe and generally occur following the administration of multiple doses. Clinical manifestations may include one or more of the following: </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>fever, rash, or severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson Syndrome); </item>
                           <item>vasculitis; arthralgia; myalgia; serum sickness; </item>
                           <item>allergic pneumonitis; </item>
                           <item>interstitial nephritis; acute renal insufficiency or failure; </item>
                           <item>hepatitis; jaundice; acute hepatic necrosis or failure; </item>
                           <item>anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other hematologic abnormalities. </item>
                        </list>
                        <paragraph>Discontinue levofloxacin immediately at the first appearance of skin rash, jaundice, or any other sign of hypersensitivity and institute supportive measures [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">
                     <id root="e7213ecf-45e8-42d5-93f5-40fb191e289f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.7 Hypersensitivity Reactions</content>
                     </title>
                     <text>
                        <paragraph>Serious and occasionally fatal hypersensitivity and/or anaphylactic reactions have been reported in patients receiving therapy with fluoroquinolones, including levofloxacin. These reactions often occur following the first dose. Some reactions have been accompanied by cardiovascular collapse, hypotension/shock, seizure, loss of consciousness, tingling, angioedema (including tongue, laryngeal, throat, or facial edema/swelling), airway obstruction (including bronchospasm, shortness of breath, and acute respiratory distress), dyspnea, urticaria, itching, and other serious skin reactions. Levofloxacin should be discontinued immediately at the first appearance of a skin rash or any other sign of hypersensitivity. Serious acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>]<content styleCode="italics">. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d5113ac6-9819-4e88-9a70-e37a6d8636ae">
                     <id root="4ddb55ae-9ffc-44d3-b743-f493e744191c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.8 Hepatotoxicity</content>
                     </title>
                     <text>
                        <paragraph>Post-marketing reports of severe hepatotoxicity (including acute hepatitis and fatal events) have been received for patients treated with levofloxacin. No evidence of serious drug-associated hepatotoxicity was detected in clinical trials of over 7,000 patients. Severe hepatotoxicity generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days. Most cases of severe hepatotoxicity were not associated with hypersensitivity [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>]. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d2d413d2-2be2-4526-b1a0-06a3e2f20fea">
                     <id root="16d0fa51-3ee1-4b7d-9452-567531729479"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.9 <content styleCode="italics">Clostridium difficile</content>-Associated Diarrhea</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridium difficile</content>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including levofloxacin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </paragraph>
                        <paragraph> If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <content styleCode="italics">C. difficile,</content> and surgical evaluation should be instituted as clinically indicated [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_71d889d7-4aa5-4a9e-be77-c35b07f024d4">6.2</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>]<content styleCode="italics">. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_829decb8-4312-4a6c-9665-e116246457b1">
                     <id root="b9e7455c-a75b-48a9-9c23-9f9f51ebb7a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.10 Prolongation of the QT Interval</content>
                     </title>
                     <text>
                        <paragraph>Some fluoroquinolones, including levofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including levofloxacin. Levofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_bdbfd5b5-5f2a-4f7b-a066-c2a95c73d8d9">6.3</linkHtml>)</content>; <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</linkHtml>)</content>; and <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>]<content styleCode="italics">. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">
                     <id root="1ca65c0d-0e39-4470-92d9-46a87ff82f2a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.11 Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is indicated in pediatric patients (6 months of age and older) only for the prevention of inhalational anthrax (post-exposure) and for plague [see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_8eacae28-b314-4a45-9357-42bea6ffb8d8">1.7</linkHtml>, <linkHtml href="#LINK_5f968ece-0395-425c-90a2-175b5911e7a8">1.8</linkHtml>)</content>]. An increased incidence of musculoskeletal disorders (arthralgia, arthritis, tendinopathy, and gait abnormality) compared to controls has been observed in pediatric patients receiving levofloxacin [see <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</linkHtml>)</content>].</paragraph>
                        <paragraph>In immature rats and dogs, the oral and intravenous administration of levofloxacin resulted in increased osteochondrosis. Histopathological examination of the weight-bearing joints of immature dogs dosed with levofloxacin revealed persistent lesions of the cartilage. Other fluoroquinolones also produce similar erosions in the weight-bearing joints and other signs of arthropathy in immature animals of various species [see <content styleCode="bold">Animal Toxicology and/or Pharmacology (<linkHtml href="#LINK_5db87c74-a8b2-48e6-84c5-01dd8fb44315">13.2</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6accbecc-fe38-495e-9d5a-282edd2a21db">
                     <id root="6b20b462-c31c-4077-9930-cac343f3a713"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.12 Blood Glucose Disturbances</content>
                     </title>
                     <text>
                        <paragraph>As with other fluoroquinolones, disturbances of blood glucose, including symptomatic hyper- and hypoglycemia, have been reported with levofloxacin, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended. If a hypoglycemic reaction occurs in a patient being treated with levofloxacin, levofloxacin should be discontinued and appropriate therapy should be initiated immediately [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_71d889d7-4aa5-4a9e-be77-c35b07f024d4">6.2</linkHtml>)</content>; <content styleCode="bold">DRUG INTERACTIONS (<linkHtml href="#LINK_f33fa37c-013c-45e1-b312-279c547469a4">7.3</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_59fd1e07-797c-41c8-82d3-b6597c3fddc1">17.4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_237163c2-7d5c-47cc-927d-00589d6803d1">
                     <id root="0c20660b-52ae-41e1-8065-ebda9a34f898"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.13 Photosensitivity/Phototoxicity</content>
                     </title>
                     <text>
                        <paragraph>Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, “V” area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of fluoroquinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if photosensitivity/phototoxicity occurs [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_bdbfd5b5-5f2a-4f7b-a066-c2a95c73d8d9">6.3</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_683559af-c23d-4c3a-9d96-d55a6eeecd6e">17.3</linkHtml>)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5609ee2e-b56d-4838-8886-05b1421a5efc">
                     <id root="1e8a642e-4522-4405-8b7a-ea31efe32728"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.14 Development of Drug Resistant Bacteria</content>
                     </title>
                     <text>
                        <paragraph>Prescribing levofloxacin in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug‑resistant bacteria [see <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_372f9005-d57d-43db-9534-f6fedc9f4dc7">17.2</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">
               <id root="8ff5147a-d111-4778-bc44-8e363d7fa575"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20160815"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common reactions (≥ 3%) were nausea, headache, diarrhea, insomnia, constipation and dizziness (<linkHtml href="#LINK_71d889d7-4aa5-4a9e-be77-c35b07f024d4">6.2</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-233-2001, or the FDA at 1-800-FDA-1088 or <linkHtml href="#medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_38344cce-d4d7-4566-8a4a-28ff594d1902">
                     <id root="c8350760-f089-4e1b-b324-48ff2e91b61b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 Serious and Otherwise Important Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Disabling and Potentially Irreversible Serious Adverse Reactions [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_0991ea01-74a1-403b-851a-36a06ec4872e">5.1</linkHtml>)</content>]</item>
                           <item>Tendinitis and Tendon Rupture [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">5.2</linkHtml>)</content>]</item>
                           <item>Peripheral Neuropathy [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_7a390283-f0a5-4bf0-9f4a-be9c29fd2fcb">5.3</linkHtml>)</content>]</item>
                           <item>Central Nervous System Effects [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>]</item>
                           <item>Exacerbation of Myasthenia Gravis [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_aaee3dd2-757e-45de-815b-91e5d8b415e6">5.5</linkHtml>)</content>]</item>
                           <item>Other Serious and Sometimes Fatal Reactions [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>]</item>
                           <item>Hypersensitivity Reactions [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>)</content>]</item>
                           <item>Hepatotoxicity [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_d5113ac6-9819-4e88-9a70-e37a6d8636ae">5.8</linkHtml>)</content>]</item>
                           <item>Clostridium difficile-Associated Diarrhea [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_d2d413d2-2be2-4526-b1a0-06a3e2f20fea">5.9</linkHtml>)</content>] </item>
                           <item>Prolongation of the QT Interval [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_829decb8-4312-4a6c-9665-e116246457b1">5.10</linkHtml>)</content>]</item>
                           <item>Musculoskeletal Disorders in Pediatric Patients [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.11</linkHtml>)</content>]</item>
                           <item>Blood Glucose Disturbances [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_6accbecc-fe38-495e-9d5a-282edd2a21db">5.12</linkHtml>)</content>]</item>
                           <item>Photosensitivity/Phototoxicity [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_237163c2-7d5c-47cc-927d-00589d6803d1">5.13</linkHtml>)</content>]</item>
                           <item>Development of Drug Resistant Bacteria [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_5609ee2e-b56d-4838-8886-05b1421a5efc">5.14</linkHtml>)</content>]   </item>
                        </list>
                        <paragraph>Hypotension has been associated with rapid or bolus intravenous infusion of levofloxacin. Levofloxacin should be infused slowly over 60 to 90 minutes, depending on dosage [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_c66ccf10-2cdb-4177-a8c1-87592e9d2b62">2.5</linkHtml>)</content>].</paragraph>
                        <paragraph>Crystalluria and cylindruria have been reported with quinolones, including levofloxacin. Therefore, adequate hydration of patients receiving levofloxacin should be maintained to prevent the formation of a highly concentrated urine [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_c66ccf10-2cdb-4177-a8c1-87592e9d2b62">2.5</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_71d889d7-4aa5-4a9e-be77-c35b07f024d4">
                     <id root="88e7f517-c5bd-493d-a9e4-d691c4a4bfa3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6.2 Clinical Trial Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The data described below reflect exposure to levofloxacin in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was &lt; 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with levofloxacin for a wide variety of infectious diseases [see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">1</linkHtml>)</content>]. Patients received levofloxacin doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily. Treatment duration was usually 3–14 days, and the mean number of days on therapy was 10 days.</paragraph>
                        <paragraph>The overall incidence, type and distribution of adverse reactions was similar in patients receiving levofloxacin doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of levofloxacin due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily nausea (0.6%); vomiting (0.4%); dizziness (0.3%); and headache (0.2%). The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily nausea (0.6%), vomiting (0.5%); dizziness (0.3%); and headache (0.3%).</paragraph>
                        <paragraph>Adverse reactions occurring in ≥ 1% of levofloxacin-treated patients and less common adverse reactions, occurring in 0.1 to &lt; 1% of levofloxacin-treated patients, are shown in <content styleCode="bold">Table 4 </content>and <content styleCode="bold">Table 5</content>, respectively. The most common adverse drug reactions (≥ 3%) are nausea, headache, diarrhea, insomnia, constipation, and dizziness.</paragraph>
                        <table>
                           <caption>Table 4: Common (≥ 1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin</caption>
                           <col width="8cm"/>
                           <col width="9cm"/>
                           <col width="2cm"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">System/Organ Class</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">%<br/>(N = 7537)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Infections and Infestations</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>moniliasis</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>insomnia<footnote ID="FOOT_9310">N = 7274</footnote> [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>] </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Nervous System Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>headache<br/>dizziness [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>]</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6<br/>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>dyspnea [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>)</content>]</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>nausea <br/>diarrhea <br/>constipation <br/>abdominal pain <br/>vomiting <br/>dyspepsia</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7<br/>5<br/>3<br/>2<br/>2<br/>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Skin and Subcutaneous Tissue Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>rash [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>)</content>] <br/>pruritus</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>2<br/>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Reproductive System and Breast Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>vaginitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1<footnote ID="FOOT_9311">N = 3758 (women)</footnote> </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>edema<br/>injection site reaction<br/>chest pain</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1<br/>1<br/>1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table>
                           <caption>Table 5: Less Common (0.1 to 1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin (N = 7537)</caption>
                           <col width="191.4pt"/>
                           <col width="347.25pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">System/Organ Class</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Infections and Infestations</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>genital moniliasis</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Blood and Lymphatic System Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>anemia<br/>thrombocytopenia<br/>granulocytopenia <br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Immune System Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>allergic reaction [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>, <linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Metabolism and Nutrition Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>hyperglycemia<br/>hypoglycemia<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_6accbecc-fe38-495e-9d5a-282edd2a21db">5.12</linkHtml>)</content>] <br/>hyperkalemia</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>anxiety<br/>agitation<br/>confusion<br/>depression<br/>hallucination<br/>nightmare<footnote ID="FOOT_9312">N = 7274</footnote> <br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>] <br/>sleep disorder<footnoteRef IDREF="FOOT_9312"/> <br/>anorexia<br/>abnormal dreaming<footnoteRef IDREF="FOOT_9312"/> </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Nervous System Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>tremor<br/>convulsions<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>] <br/>paresthesia [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_7a390283-f0a5-4bf0-9f4a-be9c29fd2fcb">5.3</linkHtml>)</content>] <br/>vertigo<br/>hypertonia<br/>hyperkinesias<br/>abnormal gait<br/>somnolence<footnoteRef IDREF="FOOT_9312"/> <br/>syncope</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>epistaxis </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Cardiac Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>cardiac arrest <br/>palpitation<br/>ventricular tachycardia<br/>ventricular arrhythmia</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Vascular Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>phlebitis</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>gastritis<br/>stomatitis<br/>pancreatitis<br/>esophagitis<br/>gastroenteritis<br/>glossitis<br/>pseudomembranous / <content styleCode="italics">C. difficile</content> colitis [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_d2d413d2-2be2-4526-b1a0-06a3e2f20fea">5.9</linkHtml>)</content>] </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Hepatobiliary Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>abnormal hepatic function <br/>increased hepatic enzymes<br/>increased alkaline phosphatase </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>urticaria [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>arthralgia<br/>tendinitis<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.11</linkHtml>)</content>] <br/>myalgia<br/>skeletal pain </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Renal and Urinary Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>abnormal renal function<br/>acute renal failure [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with quinolones, including levofloxacin. The relationship of the drugs to these events is not presently established.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_bdbfd5b5-5f2a-4f7b-a066-c2a95c73d8d9">
                     <id root="fb64e08a-a05e-4c22-82b0-f5db00d9200a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">6.3 Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>Table 6 lists adverse reactions that have been identified during post-approval use of levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.</paragraph>
                        <table>
                           <caption>Table 6: Postmarketing Reports Of Adverse Drug Reactions</caption>
                           <col width="8cm"/>
                           <col width="11cm"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">System/Organ Class</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Blood and Lymphatic System Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>pancytopenia<br/>aplastic anemia<br/>leukopenia<br/>hemolytic anemia<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>] <br/>eosinophilia </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Immune System Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>hypersensitivity reactions, sometimes fatal including:<br/>  anaphylactic/anaphylactoid reactions<br/>  anaphylactic shock<br/>  angioneurotic edema<br/>  serum sickness<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>, <linkHtml href="#LINK_1bd7e834-3bbd-47b6-9794-f13e51b6b1e7">5.7</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>psychosis<br/>paranoia<br/>isolated reports of suicide attempt and suicidal ideation<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>] </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Nervous System Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>exacerbation of myasthenia gravis [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_aaee3dd2-757e-45de-815b-91e5d8b415e6">5.2</linkHtml>)</content>]<br/>anosmia<br/>ageusia<br/>parosmia<br/>dysgeusia<br/>peripheral neuropathy (may be irreversible) [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_7a390283-f0a5-4bf0-9f4a-be9c29fd2fcb">5.3</linkHtml>)</content>] <br/>isolated reports of encephalopathy<br/>abnormal electroencephalogram (EEG)<br/>dysphonia<br/>pseudotumor cerebri [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Eye Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>uveitis<br/>vision disturbance, including diplopia<br/>visual acuity reduced<br/>vision blurred<br/>scotoma</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Ear and Labyrinth Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>hypoacusis<br/>tinnitus</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Cardiac Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>isolated reports of torsade de pointes<br/>electrocardiogram QT prolonged<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_829decb8-4312-4a6c-9665-e116246457b1">5.10</linkHtml>)</content>] <br/>tachycardia</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Vascular Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>vasodilatation</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>isolated reports of allergic pneumonitis [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Hepatobiliary Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>hepatic failure (including fatal cases)<br/>hepatitis<br/>jaundice<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>, <linkHtml href="#LINK_d5113ac6-9819-4e88-9a70-e37a6d8636ae">5.8</linkHtml>)</content>] </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Skin and Subcutaneous Tissue Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>bullous eruptions to include:<br/>  Stevens-Johnson Syndrome<br/>  toxic epidermal necrolysis<br/>  erythema multiforme<br/>[see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>] <br/>photosensitivity/phototoxicity reaction [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_237163c2-7d5c-47cc-927d-00589d6803d1">5.13</linkHtml>)</content>] <br/>leukocytoclastic vasculitis</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal and</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Connective Tissue Disorders </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>tendon rupture [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">5.2</linkHtml>)</content>] <br/>muscle injury, including rupture<br/>rhabdomyolysis</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Renal and Urinary Disorders</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>interstitial nephritis [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_288e647e-d314-4849-9e55-18178c949b0d">5.6</linkHtml>)</content>]</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">General Disorders and</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Administration Site Conditions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>multi-organ failure<br/>pyrexia</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Investigations </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>prothrombin time prolonged<br/>international normalized ratio prolonged<br/>muscle enzymes increased</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_17266c45-cb57-428f-9e0a-08815b20594d">
               <id root="84b6764f-a702-41b8-97ca-bfb7b38c2337"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20160816"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col width="134.7pt"/>
                           <col width="120.45pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Interacting Drug </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Interaction </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Multivalent cation - containing products including antacids, metal cations or didanosine </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Absorption of levofloxacin is decreased when the tablet or oral solution formulation is taken within 2 hours of these products. Do not co-administer the intravenous formulation in the same IV line with a multivalent cation, e.g., magnesium (<linkHtml href="#LINK_7a7eb258-b154-4fd3-b0de-94f5ef07cf24">2.4</linkHtml>, <linkHtml href="#LINK_52268413-8070-4f62-a6aa-1f8beb3885f1">7.1</linkHtml>) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Warfarin </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Effect may be enhanced. Monitor prothrombin time, INR, watch for bleeding (<linkHtml href="#LINK_130c5c24-04db-4baa-b08b-7f6d7e3f5cca">7.2</linkHtml>) </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Antidiabetic agents </paragraph>
                                 </td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>Carefully monitor blood glucose (<linkHtml href="#LINK_6accbecc-fe38-495e-9d5a-282edd2a21db">5.12</linkHtml>, <linkHtml href="#LINK_f33fa37c-013c-45e1-b312-279c547469a4">7.3</linkHtml>) </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_52268413-8070-4f62-a6aa-1f8beb3885f1">
                     <id root="fe74556f-7bf7-4f29-86b6-a5ca183b0ef5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 Chelation Agents: Antacids, Sucralfate, Metal Cations, Multivitamins</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Levofloxacin Injection <br/>
                           </content>There are no data concerning an interaction of intravenous fluoroquinolones with oral antacids, sucralfate, multivitamins, didanosine, or metal cations. However, no fluoroquinolone should be co-administered with any solution containing multivalent cations, e.g., magnesium, through the same intravenous line [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_c66ccf10-2cdb-4177-a8c1-87592e9d2b62">2.5</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_130c5c24-04db-4baa-b08b-7f6d7e3f5cca">
                     <id root="ccb24f71-dbe4-4c62-a1f0-c68b272c8cb7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2 Warfarin</content>
                     </title>
                     <text>
                        <paragraph>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that levofloxacin enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and levofloxacin use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if levofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_bdbfd5b5-5f2a-4f7b-a066-c2a95c73d8d9">6.3</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_59fd1e07-797c-41c8-82d3-b6597c3fddc1">17.4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f33fa37c-013c-45e1-b312-279c547469a4">
                     <id root="a176df12-dc5e-40ef-8186-ca8c7fc51117"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.3 Antidiabetic Agents</content>
                     </title>
                     <text>
                        <paragraph>Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_6accbecc-fe38-495e-9d5a-282edd2a21db">5.12</linkHtml>)</content>; <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_71d889d7-4aa5-4a9e-be77-c35b07f024d4">6.2</linkHtml>)</content>; <content styleCode="bold">PATIENT COUNSELING INFORMATION (<linkHtml href="#LINK_59fd1e07-797c-41c8-82d3-b6597c3fddc1">17.4</linkHtml>)</content>]. </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_30a94422-889f-4ef0-b3fa-2be80926bc8f">
                     <id root="8dfab3b6-d57e-4074-88e6-852e561c4684"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.4 Non-Steroidal Anti-Inflammatory Drugs</content>
                     </title>
                     <text>
                        <paragraph>The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including levofloxacin, may increase the risk of CNS stimulation and convulsive seizures [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c22078fc-57b5-4b7c-9f61-efec69ff90f4">
                     <id root="a7e4a54e-861b-4d32-845d-1a56b1dbb38f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.5 Theophylline</content>
                     </title>
                     <text>
                        <paragraph>No significant effect of levofloxacin on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when levofloxacin is co‑administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_da68872a-681b-4f73-8c30-8e6138e65875">5.4</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1ed2d7fd-0267-401e-b965-21c6a1634e3f">
                     <id root="e288c176-04f6-473b-9397-2516a0327f9c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.6 Cyclosporine</content>
                     </title>
                     <text>
                        <paragraph>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other fluoroquinolones. Levofloxacin C<sub>max</sub> and k<sub>e</sub> were slightly lower while T<sub>max</sub> and t<sub>½</sub> were slightly longer in the presence of cyclosporine than those observed in other studies without concomitant medication. The differences, however, are not considered to be clinically significant. Therefore, no dosage adjustment is required for levofloxacin or cyclosporine when administered concomitantly.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1ab191fa-a7fb-46a2-a429-d26d736881b0">
                     <id root="227de2a8-9e44-4dd6-8b20-3359a94240d9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.7 Digoxin</content>
                     </title>
                     <text>
                        <paragraph>No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for levofloxacin or digoxin is required when administered concomitantly.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1cdb8fa4-5c3b-45f8-b114-c2c27bc354e2">
                     <id root="09ea5f84-740b-42ad-a69a-24527e5ff05d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.8 Probenecid and Cimetidine</content>
                     </title>
                     <text>
                        <paragraph>No significant effect of probenecid or cimetidine on the C<sub>max</sub> of levofloxacin was observed in a clinical study involving healthy volunteers. The AUC and t<sub>½</sub> of levofloxacin were higher while CL/F and CL<sub>R</sub> were lower during concomitant treatment of levofloxacin with probenecid or cimetidine compared to levofloxacin alone. However, these changes do not warrant dosage adjustment for levofloxacin when probenecid or cimetidine is co-administered.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_43925a9d-78e4-48e3-98f0-cd95311bc00a">
                     <id root="dda87971-01f3-4af9-9052-a701fb98af50"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.9 Interactions with Laboratory or Diagnostic Testing</content>
                     </title>
                     <text>
                        <paragraph>Some fluoroquinolones, including levofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4131ba19-89d3-477d-85da-29cf4941d0e0">
               <id root="4a8973aa-501e-4b2f-9c61-15ec963b973c"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20160816"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Geriatrics: Severe hepatotoxicity has been reported. The majority of reports describe patients 65 years of age or older (<linkHtml href="#LINK_d5113ac6-9819-4e88-9a70-e37a6d8636ae">5.8</linkHtml>, <linkHtml href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</linkHtml>, <linkHtml href="#LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd">17</linkHtml>). May have increased risk of tendinopathy (including rupture), especially with concomitant corticosteroid use (<linkHtml href="#LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">5.2</linkHtml>, <linkHtml href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</linkHtml>, <linkHtml href="#LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd">17</linkHtml>). May be more susceptible to prolongation of the QT interval. (<linkHtml href="#LINK_829decb8-4312-4a6c-9665-e116246457b1">5.10</linkHtml>, <linkHtml href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</linkHtml>, <linkHtml href="#LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd">17</linkHtml>).</item>
                           <item>Pediatrics: Musculoskeletal disorders (arthralgia, arthritis, tendinopathy, and gait abnormality) seen in more levofloxacin-treated patients than in comparator. Shown to cause arthropathy and osteochondrosis in juvenile animals (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.11</linkHtml>, <linkHtml href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</linkHtml>, <linkHtml href="#LINK_5db87c74-a8b2-48e6-84c5-01dd8fb44315">13.2</linkHtml>). Safety in pediatric patients treated for more than 14 days has not been studied. Risk-benefit appropriate only for the treatment of inhalational anthrax (post-exposure) (<linkHtml href="#LINK_8eacae28-b314-4a45-9357-42bea6ffb8d8">1.7</linkHtml>, <linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>, <linkHtml href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</linkHtml>, <linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>) and plague (<linkHtml href="#LINK_5f968ece-0395-425c-90a2-175b5911e7a8">1.8</linkHtml>, <linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>, <linkHtml href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</linkHtml>, <linkHtml href="#LINK_61466cb7-0624-4e2a-8190-17b69bbd3bfb">14.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3d64c32b-83e1-4932-925c-bf3fae007911">
                     <id root="c93b5b57-3bb8-4ade-bbcd-abb3bd43909d"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>Pregnancy Category C. Levofloxacin was not teratogenic in rats at oral doses as high as 810 mg/kg/day which corresponds to 9.4 times the highest recommended human dose based upon relative body surface area, or at intravenous doses as high as 160 mg/kg/day corresponding to 1.9 times the highest recommended human dose based upon relative body surface area. The oral dose of 810 mg/kg/day to rats caused decreased fetal body weight and increased fetal mortality. No teratogenicity was observed when rabbits were dosed orally as high as 50 mg/kg/day which corresponds to 1.1 times the highest recommended human dose based upon relative body surface area, or when dosed intravenously as high as 25 mg/kg/day, corresponding to 0.5 times the highest recommended human dose based upon relative body surface area.</paragraph>
                        <paragraph>There are, however, no adequate and well-controlled studies in pregnant women. Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20141007"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_367b4528-5767-4d83-97da-5a405ca061e0">
                     <id root="c74d844e-eddf-4f13-92d3-6a895c97bd60"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>
                        <content styleCode="bold">8.3 Nursing Mothers</content>
                     </title>
                     <text>
                        <paragraph>Based on data on other fluoroquinolones and very limited data on levofloxacin, it can be presumed that levofloxacin will be excreted in human milk. Because of the potential for serious adverse reactions from levofloxacin in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2de9de63-7015-4729-94e1-92c1738623fa">
                     <id root="cc3c3e0c-0748-4ae0-b7a8-ca494209a75c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Quinolones, including levofloxacin, cause arthropathy and osteochondrosis in juvenile animals of several species [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.11</linkHtml>)</content> and <content styleCode="bold">ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY (<linkHtml href="#LINK_5db87c74-a8b2-48e6-84c5-01dd8fb44315">13.2</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pharmacokinetics following intravenous administration<br/>
                           </content>The pharmacokinetics of levofloxacin following a single intravenous dose were investigated in pediatric patients ranging in age from six months to 16 years. Pediatric patients cleared levofloxacin faster than adult patients resulting in lower plasma exposures than adults for a given mg/kg dose [see <content styleCode="bold">CLINICAL PHARMACOLOGY (<linkHtml href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</linkHtml>)</content> and <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Inhalational Anthrax (Post-Exposure) <br/>
                           </content>Levofloxacin is indicated in pediatric patients 6 months of age and older, for inhalational anthrax (post-exposure). The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate. The safety of levofloxacin in pediatric patients treated for more than 14 days has not been studied [see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_8eacae28-b314-4a45-9357-42bea6ffb8d8">1.7</linkHtml>)</content>; <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>) </content>and <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_eda5db73-92cb-4927-9490-0ee79d298e57">14.9</linkHtml>)</content>]. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Plague<br/>
                           </content>Levofloxacin is indicated in pediatric patients, 6 months of age and older, for treatment of plague, including pneumonic and septicemic plague due to <content styleCode="italics">Yersinia pestis </content>(<content styleCode="italics">Y. pestis</content>) and prophylaxis for plague. Efficacy studies of levofloxacin could not be conducted in humans with pneumonic plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals. The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate [see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_5f968ece-0395-425c-90a2-175b5911e7a8">1.8</linkHtml>)</content>; <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>)</content> and <content styleCode="bold">CLINICAL STUDIES (<linkHtml href="#LINK_61466cb7-0624-4e2a-8190-17b69bbd3bfb">14.10</linkHtml>)</content>]. </paragraph>
                        <paragraph>Safety and effectiveness in pediatric patients below the age of six months have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Events<br/>
                           </content>In clinical trials, 1534 children (6 months to 16 years of age) were treated with oral and intravenous levofloxacin. Children 6 months to 5 years of age received levofloxacin 10 mg/kg twice a day and children greater than 5 years of age received 10 mg/kg once a day (maximum 500 mg per day) for approximately 10 days.</paragraph>
                        <paragraph>A subset of children in the clinical trials (1340 levofloxacin-treated and 893 non-fluoroquinolone-treated) enrolled in a prospective, long-term surveillance study to assess the incidence of protocol-defined musculoskeletal disorders (arthralgia, arthritis, tendinopathy, gait abnormality) during 60 days and 1 year following the first dose of the study drug. Children treated with levofloxacin had a significantly higher incidence of musculoskeletal disorders when compared to the non-fluoroquinolone‑treated children as illustrated in <content styleCode="bold">Table 7</content>.</paragraph>
                        <table>
                           <caption>Table 7: Incidence of Musculoskeletal Disorders in Pediatric Clinical Trial</caption>
                           <col width="7cm"/>
                           <col width="5cm"/>
                           <col width="134.7pt"/>
                           <col width="63.75pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Follow-up Period</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Levofloxacin<br/>N = 1340</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Non-Fluoroquinolone<footnote ID="FOOT_9313">Non-Fluoroquinolone: ceftriaxone, amoxicillin / clavulanate, clarithromycin</footnote> <br/>N = 893</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">p-value<footnote ID="FOOT_9314">2-sided Fisher’s Exact Test</footnote> </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">60 days </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>28 (2.1%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>8 (0.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>p = 0.038</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">1 year<footnote ID="FOOT_9315">There were 1199 levofloxacin-treated and 804 non-fluoroquinolone-treated children who had a one-year evaluation visit. However, the incidence of musculoskeletal disorders was calculated using all reported events during the specified period for all children enrolled regardless of whether they completed the 1-year evaluation visit.</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>46 (3.4%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>16 (1.8%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>p = 0.025</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Arthralgia was the most frequently occurring musculoskeletal disorder in both treatment groups. Most of the musculoskeletal disorders in both groups involved multiple weight-bearing joints. Disorders were moderate in 8/46 (17%) children and mild in 35/46 (76%) levofloxacin-treated children and most were treated with analgesics. The median time to resolution was 7 days for levofloxacin-treated children and 9 for non-fluoroquinolone-treated children (approximately 80% resolved within 2 months in both groups). No child had a severe or serious disorder and all musculoskeletal disorders resolved without sequelae. </paragraph>
                        <paragraph>Vomiting and diarrhea were the most frequently reported adverse events, occurring in similar frequency in the levofloxacin-treated and non-fluoroquinolone-treated children.</paragraph>
                        <paragraph>In addition to the events reported in pediatric patients in clinical trials, events reported in adults during clinical trials or post-marketing experience [see <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_9144420f-d7c5-4c9d-b8f4-8e5ce7f9909b">6</linkHtml>)</content>] may also be expected to occur in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">
                     <id root="1e543782-da4e-42df-812b-5926fd05b223"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as levofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing levofloxacin to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue levofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur [see <content styleCode="bold">
                              <linkHtml href="#LINK_a8e87156-1790-4479-b994-930898fd7c9e">Boxed Warning</linkHtml>
                           </content>; <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_10b867ee-c48f-4bef-8c8f-e9bd9f0ff6ba">5.2</linkHtml>) </content>and <content styleCode="bold">ADVERSE REACTIONS (<linkHtml href="#LINK_bdbfd5b5-5f2a-4f7b-a066-c2a95c73d8d9">6.3</linkHtml>)</content>]. </paragraph>
                        <paragraph>In phase 3 clinical trials, 1,945 levofloxacin-treated patients (26%) were ≥ 65 years of age. Of these, 1,081 patients (14%) were between the ages of 65 and 74 and 864 patients (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>Severe, and sometimes fatal, cases of hepatotoxicity have been reported post-marketing in association with levofloxacin. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_d5113ac6-9819-4e88-9a70-e37a6d8636ae">5.8</linkHtml>)</content>].</paragraph>
                        <paragraph>Elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using levofloxacin with concomitant drugs that can result in prolongation of the QT interval (e.g., Class IA or Class III antiarrhythmics) or in patients with risk factors for torsade de pointes (e.g., known QT prolongation, uncorrected hypokalemia) [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_829decb8-4312-4a6c-9665-e116246457b1">5.10</linkHtml>)</content>].</paragraph>
                        <paragraph>The pharmacokinetic properties of levofloxacin in younger adults and elderly adults do not differ significantly when creatinine clearance is taken into consideration. However, since the drug is known to be substantially excreted by the kidney, the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see <content styleCode="bold">CLINICAL PHARMACOLOGY (<linkHtml href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7e047670-63c8-4b2f-9dda-d2261568eaa3">
                     <id root="24ca3c8e-1536-4049-a38c-2aa29cc39adc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.6 Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in patients with impaired renal function (creatinine clearance &lt; 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_c56b5e0e-be06-4991-9c8f-e3fb91021240">2.3</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_db0a0cfd-34c1-4814-ac39-7f93b95129c0">
                     <id root="a25b163a-1498-4f1b-b381-254db8ed49cd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.7 Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_76922bd7-15a9-47b4-9eed-781a842e50c2">
               <id root="62815ee1-a4bc-4774-9f57-94261ec4cc8f"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis.</paragraph>
                  <paragraph>Levofloxacin exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of levofloxacin: ataxia, ptosis, decreased locomotor activity, dyspnea, prostration, tremors, and convulsions. Doses in excess of 1500 mg/kg orally and 250 mg/kg IV produced significant mortality in rodents.</paragraph>
               </text>
               <effectiveTime value="20130801"/>
            </section>
         </component>
         <component>
            <section ID="LINK_270240c8-24da-44ce-af8d-3341abaa6a73">
               <id root="98b17ae6-a49a-4e59-be02-a321ad4f9612"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral and intravenous administration. Chemically, levofloxacin, a chiral fluorinated carboxyquinolone, is the pure (-)-(S)-enantiomer of the racemic drug substance ofloxacin. The chemical name is (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: The Chemical Structure of Levofloxacin</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>The empirical formula is C<sub>18</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>4</sub> • ½ H<sub>2</sub>O and the molecular weight is 370.38. Levofloxacin is a light yellowish‑white to yellow-white crystal or crystalline powder. The molecule exists as a zwitterion at the pH conditions in the small intestine.</paragraph>
                  <paragraph>The data demonstrate that from pH 0.6 to 5.8, the solubility of levofloxacin is essentially constant (approximately 100 mg/mL). Levofloxacin is considered <content styleCode="italics">soluble to freely soluble</content> in this pH range, as defined by USP nomenclature. Above pH 5.8, the solubility increases rapidly to its maximum at pH 6.7 (272 mg/mL) and is considered <content styleCode="italics">freely soluble</content> in this range. Above pH 6.7, the solubility decreases and reaches a minimum value (about 50 mg/mL) at a pH of approximately 6.9.</paragraph>
                  <paragraph>Levofloxacin has the potential to form stable coordination compounds with many metal ions. This <content styleCode="italics">in vitro</content> chelation potential has the following formation order: Al<sup>+3</sup>&gt;Cu<sup>+2</sup>&gt;Zn<sup>+2</sup>&gt;Mg<sup>+2</sup>&gt;Ca<sup>+2</sup>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Excipients and Description of Dosage Forms<br/>
                     </content>
                     <content styleCode="underline">Levofloxacin Injection<br/>
                     </content>The appearance of levofloxacin injection may range from a clear yellow to a clear greenish-yellow solution. This does not adversely affect product potency.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Levofloxacin Injection Premix in Single Dose Flexible Containers</content> is a sterile, preservative-free aqueous solution of levofloxacin with pH ranging from 3.8 to 5.8. This is a dilute, non-pyrogenic, nearly isotonic premixed solution that contains levofloxacin in 5% dextrose (D5W). Solutions of hydrochloric acid and sodium hydroxide may have been added to adjust the pH.</paragraph>
                  <paragraph>The flexible container is fabricated from polypropylene. The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container’s chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers.</paragraph>
               </text>
               <effectiveTime value="20160505"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Levofloxacin Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levofloxacin-injection-in-5-percent-dextrose-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b2e74910-6622-4ed1-8296-a59406ca0f2a">
               <id root="12bf0d81-65aa-421c-82b9-f31e8b947769"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20160816"/>
               <component>
                  <section ID="LINK_44e3e2c1-4e9c-49f3-9f4a-ae93ab70f634">
                     <id root="4c591b80-3214-45cc-a18c-a66850a5c3bf"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is a member of the fluoroquinolone class of antibacterial agents [see <content styleCode="bold">Microbiology (<linkHtml href="#LINK_ed3d8a3b-5eb5-4634-9172-3959fba7ebda">12.4</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20141007"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">
                     <id root="fa375761-c0c0-4d43-923e-c834cc5da2bd"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>The mean ± SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of levofloxacin are summarized in <content styleCode="bold">Table 8</content>.</paragraph>
                        <table>
                           <caption>Table 8: Mean ± SD Levofloxacin PK Parameters</caption>
                           <col width="155.95pt"/>
                           <col width="54.65pt"/>
                           <col width="54.65pt"/>
                           <col width="54.7pt"/>
                           <col width="54.65pt"/>
                           <col width="54.7pt"/>
                           <col width="54.65pt"/>
                           <col width="54.7pt"/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Regimen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">T<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">AUC</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">CL/F<footnote ID="FOOT_9316">clearance/bioavailability</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Vd/F<footnote ID="FOOT_9317">volume of distribution/bioavailability</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">t<sub>1/2</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">CL<sub>R</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">(mcg/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">(h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">(mcg∙h/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">(mL/min)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">(L)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">(h)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">(mL/min)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Single dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>250 mg oral tablet<footnote ID="FOOT_9318">healthy males 18–53 years of age</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>2.8 ± 0.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.6 ± 1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>27.2 ± 3.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>156 ± 20</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.3 ± 0.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>142 ± 21</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg oral tablet<footnoteRef IDREF="FOOT_9318"/>
                                       <sup>*</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5.1 ± 0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.3 ± 0.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>47.9 ± 6.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>178 ± 28</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6.3 ± 0.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>103 ± 30</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg oral solution<footnote ID="FOOT_9327">healthy males and females 19–55 years of age</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5.8 ± 1.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>0.8 ± 0.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>47.8 ± 10.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>183 ± 40</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>112 ± 37.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.0 ± 1.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg IV<footnoteRef IDREF="FOOT_9318"/> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6.2 ± 1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.0 ± 0.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>48.3 ± 5.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>175 ± 20</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>90 ± 11</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6.4 ± 0.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>112 ± 25</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>750 mg oral tablet<footnote ID="FOOT_9320">healthy male and female subjects 18–54 years of age</footnote>
                                       <sup>*</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>9.3 ± 1.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.6 ± 0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>101 ± 20</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>129 ± 24</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>83 ± 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.5 ± 0.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>750 mg IV<footnoteRef IDREF="FOOT_9320"/>  </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>11.5 ± 4.0<footnote ID="FOOT_9319">60 min infusion for 250 mg and 500 mg doses, 90 min infusion for 750 mg dose</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>110 ± 40</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>126 ± 39</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>75 ± 13</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.5 ± 1.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Multiple dose</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg every 24h oral tablet<footnoteRef IDREF="FOOT_9318"/> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5.7 ± 1.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.1 ± 0.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>47.5 ± 6.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>175 ± 25</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>102 ± 22</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.6 ± 1.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>116 ± 31</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg every 24h IV<footnoteRef IDREF="FOOT_9318"/> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6.4 ± 0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>54.6 ± 11.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>158 ± 29</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>91 ± 12</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.0 ± 0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>99 ± 28</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>500 mg or 250 mg every 24h IV, patients with bacterial infection<footnote ID="FOOT_9321">500 mg every 48h for patients with moderate renal impairment (CLCR 20–50 mL/min) and infections of the respiratory tract or skin</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>8.7± 4.0<footnote ID="FOOT_9322">dose-normalized values (to 500 mg dose), estimated by population pharmacokinetic modeling</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>72.5 ± 51.2<footnoteRef IDREF="FOOT_9322"/> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>154 ± 72</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>111 ± 58</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>750 mg every 24h oral tablet<footnoteRef IDREF="FOOT_9320"/> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>8.6 ± 1.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.4 ± 0.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>90.7 ± 17.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>143 ± 29</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>100 ± 16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>8.8 ± 1.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>116 ± 28</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>750 mg every 24h IV<footnoteRef IDREF="FOOT_9320"/> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>12.1 ± 4.1<footnoteRef IDREF="FOOT_9319"/> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>108 ± 34</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>126 ± 37</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>80 ± 27</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.9 ± 1.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">500 mg oral tablet single dose, effects of gender and age:</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Male<footnote ID="FOOT_9323">healthy males 22–75 years of age</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5.5 ± 1.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.2 ± 0.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>54.4 ± 18.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>166 ± 44</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>89 ± 13</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.5 ± 2.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>126 ± 38</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Female<footnote ID="FOOT_9324">healthy females 18–80 years of age</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.0 ± 1.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.7 ± 0.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>67.7 ± 24.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>136 ± 44</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>62 ± 16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6.1 ± 0.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>106 ± 40</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Young<footnote ID="FOOT_9325">young healthy male and female subjects 18–36 years of age</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5.5 ± 1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.5 ± 0.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>47.5 ± 9.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>182 ± 35</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>83 ± 18</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6.0 ± 0.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>140 ± 33</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Elderly<footnote ID="FOOT_9326">healthy elderly male and female subjects 66–80 years of age</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.0 ± 1.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.4 ± 0.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>74.7 ± 23.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>121 ± 33</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>67 ± 19</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.6 ± 2.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>91 ± 29</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="8" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">500 mg oral single dose tablet, patients with renal insufficiency:</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>CLCR 50–80 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.5 ± 1.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.5 ± 0.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>95.6 ± 11.8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>88 ± 10</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>9.1 ± 0.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>57 ± 8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>CLCR 20–49 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7.1 ± 3.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>2.1 ± 1.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>182.1 ± 62.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>51 ± 19</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>27 ± 10</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>26 ± 13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>CLCR &lt; 20 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>8.2 ± 2.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.1 ± 1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>263.5 ± 72.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>33 ± 8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>35 ± 5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>13 ± 3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Hemodialysis</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5.7 ± 1.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>2.8 ± 2.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>76 ± 42</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>CAPD</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6.9 ± 2.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>1.4 ± 1.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>51 ± 24</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>ND</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>* </sup>Absolute bioavailability; F = 0.99 ± 0.08 from a 500 mg tablet and F = 0.99 ± 0.06 from a 750 mg tablet;<br/>ND = not determined.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Absorption <br/>
                           </content>Following a single intravenous dose of levofloxacin to healthy volunteers, the mean ± SD peak plasma concentration attained was 6.2 ±1.0 mcg/mL after a 500 mg dose infused over 60 minutes and 11.5 ± 4.0 mcg/mL after a 750 mg dose infused over 90 minutes. </paragraph>
                        <paragraph>Levofloxacin pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Steady‑state conditions are reached within 48 hours following a 500 mg or 750 mg once-daily dosage regimen. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 ± 1.4 and 0.5 ±0.2 mcg/mL after the 500 mg doses, and 8.6 ± 1.9 and 1.1 ± 0.4 mcg/mL after the 750 mg doses, respectively. The mean ± SD peak and trough plasma concentrations attained following multiple once‑daily IV regimens were approximately 6.4 ± 0.8 and 0.6 ± 0.2 mcg/mL after the 500 mg doses, and 12.1 ± 4.1 and 1.3 ± 0.71 mcg/mL after the 750 mg doses, respectively. </paragraph>
                        <paragraph>The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for levofloxacin tablets when equal doses (mg/mg) are administered. Therefore, the oral and IV routes of administration can be considered interchangeable (see <content styleCode="bold">Figure 2</content> and <content styleCode="bold">Figure 3</content>).</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 2: Mean Levofloxacin Plasma<br/>Concentration vs. Time Profile: 750 mg</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> <renderMultiMedia referencedObject="MM2"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3: Mean Levofloxacin Plasma<br/>Concentration vs. Time Profile: 500 mg</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> <renderMultiMedia referencedObject="MM3"/>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution<br/>
                           </content>The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin reaches its peak levels in skin tissues and in blister fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the blister fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of levofloxacin, respectively, to healthy subjects. Levofloxacin also penetrates well into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations and ranged from approximately 2.4 to 11.3 mcg/g over a 24-hour period after a single 500 mg oral dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>, over a clinically relevant range (1 to 10 mcg/mL) of serum/plasma levofloxacin concentrations, levofloxacin is approximately 24 to 38% bound to serum proteins across all species studied, as determined by the equilibrium dialysis method. Levofloxacin is mainly bound to serum albumin in humans. Levofloxacin binding to serum proteins is independent of the drug concentration.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Metabolism <br/>
                           </content>Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Excretion <br/>
                           </content>Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of levofloxacin occurs in the renal proximal tubule. No levofloxacin crystals were found in any of the urine samples freshly collected from subjects receiving levofloxacin.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Geriatric <br/>
                           </content>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects when the subjects’ differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of levofloxacin to healthy elderly subjects (66 – 80 years of age), the mean terminal plasma elimination half-life of levofloxacin was about 7.6 hours, as compared to approximately 6 hours in younger adults. The difference was attributable to the variation in renal function status of the subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by age. Levofloxacin dose adjustment based on age alone is not necessary [see <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_313c8236-c268-4d4e-8899-6c558f8f3a58">8.5</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Pediatrics <br/>
                           </content>The pharmacokinetics of levofloxacin following a single 7 mg/kg intravenous dose were investigated in pediatric patients ranging in age from 6 months to 16 years. Pediatric patients cleared levofloxacin faster than adult patients, resulting in lower plasma exposures than adults for a given mg/kg dose. Subsequent pharmacokinetic analyses predicted that a dosage regimen of 8 mg/kg every 12 hours (not to exceed 250 mg per dose) for pediatric patients 6 months to 17 years of age would achieve comparable steady state plasma exposures (AUC<sub>0-24</sub> and C<sub>max</sub>) to those observed in adult patients administered 500 mg of levofloxacin once every 24 hours.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Gender <br/>
                           </content>There are no significant differences in levofloxacin pharmacokinetics between male and female subjects when subjects’ differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of levofloxacin to healthy male subjects, the mean terminal plasma elimination half-life of levofloxacin was about 7.5 hours, as compared to approximately 6.1 hours in female subjects. This difference was attributable to the variation in renal function status of the male and female subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by the gender of the subjects. Dose adjustment based on gender alone is not necessary.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Race <br/>
                           </content>The effect of race on levofloxacin pharmacokinetics was examined through a covariate analysis performed on data from 72 subjects: 48 white and 24 non-white. The apparent total body clearance and apparent volume of distribution were not affected by the race of the subjects.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Renal Impairment <br/>
                           </content>Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in adult patients with impaired renal function (creatinine clearance &lt; 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD [see <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_c56b5e0e-be06-4991-9c8f-e3fb91021240">2.3</linkHtml>)</content>; <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_7e047670-63c8-4b2f-9dda-d2261568eaa3">8.6</linkHtml>)</content>].</paragraph>
                        <paragraph>
                           <content styleCode="bold">Hepatic Impairment <br/>
                           </content>Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment [see <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_db0a0cfd-34c1-4814-ac39-7f93b95129c0">8.7</linkHtml>)</content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Bacterial Infection <br/>
                           </content>The pharmacokinetics of levofloxacin in patients with serious community-acquired bacterial infections are comparable to those observed in healthy subjects.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Drug-Drug Interactions <br/>
                           </content>The potential for pharmacokinetic drug interactions between levofloxacin and antacids, warfarin, theophylline, cyclosporine, digoxin, probenecid, and cimetidine has been evaluated [see <content styleCode="bold">DRUG INTERACTIONS (<linkHtml href="#LINK_17266c45-cb57-428f-9e0a-08815b20594d">7</linkHtml>)</content>].</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 2: Mean Levofloxacin Plasma Concentration vs. Time Profile: 750 mg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="levofloxacin-injection-in-5-percent-dextrose-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Figure 3: Mean Levofloxacin Plasma Concentration vs. Time Profile: 500 mg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="levofloxacin-injection-in-5-percent-dextrose-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ed3d8a3b-5eb5-4634-9172-3959fba7ebda">
                     <id root="c1604292-34fd-4388-b822-392536520803"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>
                        <content styleCode="bold">12.4 Microbiology</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Mechanism of Action <br/>
                           </content>Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Mechanism of Resistance <br/>
                           </content>Fluoroquinolone resistance can arise through mutations in defined regions of DNA gyrase or topoisomerase IV, termed the Quinolone-Resistance Determining Regions (QRDRs), or through altered efflux.</paragraph>
                        <paragraph>Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from aminoglycosides, macrolides and β-lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials.</paragraph>
                        <paragraph>Resistance to levofloxacin due to spontaneous mutation <content styleCode="italics">in vitro</content> is a rare occurrence (range: 10<sup>-9</sup> to 10<sup>-10</sup>). Although cross‑resistance has been observed between levofloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to levofloxacin.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Activity <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo<br/>
                              </content>
                           </content>Levofloxacin has<content styleCode="italics"> in vitro</content> activity against Gram-negative and Gram-positive bacteria.<br/>Levofloxacin has been shown to be active against most isolates of the following bacteria both <content styleCode="italics">in vitro </content>and in clinical infections as described in <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_89e216a7-8b92-49d4-ada0-96ac04abc313">1</linkHtml>):</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">      Gram-Positive Bacteria<br/>
                           </content>
                           <content styleCode="italics">                Enterococcus faecalis<br/>
                           </content>
                           <content styleCode="italics">                </content>
                           <content styleCode="italics">Staphylococcus aureus</content> (methicillin-susceptible isolates)<br/>
                           <content styleCode="italics">                Staphylococcus epidermidis </content>(methicillin-susceptible isolates)<br/>                Staphylococcus saprophyticus<br/>
                           <content styleCode="italics">                Streptococcus pneumoniae</content> (including multi-drug resistant isolates [MDRSP])<footnote ID="FOOT_9344">MDRSP (Multi-drug resistant <content styleCode="italics">Streptococcus pneumoniae</content>) isolates are isolates resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 mcg/mL), 2<sup>nd</sup> generation cephalosporins, e.g., cefuroxime; macrolides, tetracyclines and trimethoprim/sulfamethoxazole.</footnote> <br/>                <content styleCode="italics">Streptococcus pyogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="bold">      </content>Gram-Negative Bacteria<br/>
                           </content>
                           <content styleCode="italics">                Enterobacter cloacae<br/>
                           </content>
                           <content styleCode="italics">                </content>
                           <content styleCode="italics">Escherichia coli<br/>
                           </content>
                           <content styleCode="italics">                Haemophilus influenzae<br/>
                           </content>
                           <content styleCode="italics">                Haemophilus parainfluenzae<br/>
                           </content>
                           <content styleCode="italics">                </content>
                           <content styleCode="italics">Klebsiella pneumoniae<br/>
                           </content>
                           <content styleCode="italics">                Legionella pneumophila<br/>
                           </content>
                           <content styleCode="italics">                Moraxella catarrhalis<br/>
                           </content>
                           <content styleCode="italics">                Proteus mirabilis<br/>
                           </content>
                           <content styleCode="italics">                </content>
                           <content styleCode="italics">Pseudomonas aeruginosa<br/>
                           </content>
                           <content styleCode="italics">                Serratia marcescens</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">      Other Bacteria<br/>
                           </content>
                           <content styleCode="italics">                Chlamydophila pneumoniae<br/>
                           </content>
                           <content styleCode="italics">                Mycoplasma pneumoniae</content>
                        </paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro </content>data are available, <content styleCode="underline">but their clinical significance is unknown</content>
                           <content styleCode="bold">: </content>Levofloxacin exhibits<content styleCode="italics"> in vitro</content> minimum inhibitory concentrations (MIC values) of 2 mcg/mL or less against most (≥ 90%) isolates of the following microorganisms; however, the safety and effectiveness of levofloxacin in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="bold">      </content>Gram-Positive Bacteria<br/>
                           </content>
                           <content styleCode="italics">                Staphylococcus haemolyticus<br/>
                           </content>                β-hemolytic <content styleCode="italics">Streptococcus </content>(Group C/F)<br/>                β-hemolytic <content styleCode="italics">Streptococcus </content>(Group G)<br/>
                           <content styleCode="italics">                Streptococcus agalactiae<br/>
                           </content>
                           <content styleCode="italics">                Streptococcus milleri<br/>
                           </content>                Viridans group <content styleCode="italics">streptococci</content>
                           <content styleCode="italics">
                              <content styleCode="italics">
                                 <br/>
                              </content>                Bacillus anthracis<br/>
                              <br/>
                           </content>
                           <content styleCode="bold">      Gram-Negative Bacteria<br/>
                           </content>
                           <content styleCode="italics">                Acinetobacter baumannii<br/>
                           </content>
                           <content styleCode="italics">                Acinetobacter lwoffii<br/>
                           </content>
                           <content styleCode="italics">                Bordetella pertussis<br/>
                           </content>
                           <content styleCode="italics">                Citrobacter koseri<br/>
                           </content>
                           <content styleCode="italics">                </content>
                           <content styleCode="italics">Citrobacter freundii<br/>
                           </content>
                           <content styleCode="italics">                Enterobacter aerogenes<br/>
                           </content>
                           <content styleCode="italics">                Enterobacter sakazakii<br/>
                           </content>
                           <content styleCode="italics">                Klebsiella oxytoca<br/>
                           </content>
                           <content styleCode="italics">                Morganella morganii<br/>
                           </content>
                           <content styleCode="italics">                Pantoea agglomerans<br/>
                           </content>
                           <content styleCode="italics">                Proteus vulgaris<br/>
                           </content>
                           <content styleCode="italics">                Providencia rettgeri<br/>
                           </content>
                           <content styleCode="italics">                Providencia stuartii<br/>
                           </content>
                           <content styleCode="italics">                Pseudomonas fluorescens<br/>
                              <content styleCode="italics">               Yersinia pestis</content>
                              <br/>
                           </content>
                           <content styleCode="bold"> <br/>
                           </content>
                           <content styleCode="bold">      Anaerobic Gram-Positive Bacteria<br/>
                           </content>
                           <content styleCode="italics">                </content>
                           <content styleCode="italics">Clostridium perfringens</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Susceptibility Tests<br/>
                           </content>When available, the clinical microbiology laboratory should provide the results of <content styleCode="italics">in vitro</content> susceptibility test results for antimicrobial drug products used in the resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="bold">         </content>Dilution techniques:<br/>
                           </content>Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC values should be determined using a standardized procedure. Standardized procedures are based on a dilution method<sup>1,2,4</sup> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of levofloxacin powder. The MIC values should be interpreted according to the criteria outlined in <content styleCode="bold">Table 9</content>. </paragraph>
                        <paragraph>         <content styleCode="bold">Diffusion techniques:<br/>
                           </content>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<sup>2,3</sup> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg levofloxacin to test the susceptibility of bacteria to levofloxacin.</paragraph>
                        <paragraph>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg levofloxacin disk should be interpreted according to the criteria outlined in <content styleCode="bold">Table 9</content>. </paragraph>
                        <table>
                           <caption> Table 9: Susceptibility Test Interpretive Criteria for Levofloxacin</caption>
                           <col width="148.85pt"/>
                           <col width="64.95pt"/>
                           <col width="64.95pt"/>
                           <col width="65pt"/>
                           <col width="64.95pt"/>
                           <col width="64.95pt"/>
                           <col width="65pt"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> </td>
                                 <td align="center" colspan="3" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <content styleCode="bold">Minimum Inhibitory<br/>Concentrations (mcg/mL)</content> </td>
                                 <td align="center" colspan="3" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <content styleCode="bold">Disk Diffusion<br/>(zone diameter in mm)</content> </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Pathogen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">S</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">I</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">R</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">S</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">I</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">R</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Enterobacteriaceae </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>14–16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Enterococcus faecalis</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>14–16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Staphylococcus</content> species</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>14–16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Pseudomonas aeruginosa</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>14–16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Haemophilus influenzae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>—<footnote ID="FOOT_9343">The current absence of data on resistant isolates precludes defining any categories other than “Susceptible”. Isolates yielding MIC /zone diameter results suggestive of a “nonsusceptible” category should be submitted to a reference laboratory for further testing.</footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>—</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Haemophilus parainfluenzae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Streptococcus pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>14–16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Streptococcus pyogenes</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 8</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≥ 17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>14–16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>≤ 13</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <content styleCode="italics">Yersinia </content>
                                    <content styleCode="italics">pesti</content>s<sup>4</sup>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top"> ≤ 0.25</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">— </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">— </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <content styleCode="italics">Bacillus anthracis</content>
                                    <sup>4</sup>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">≤ 0.25</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">—</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">— </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">— </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">— </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>S = Susceptible, I = Intermediate, R = Resistant</paragraph>
                        <paragraph>A report of <content styleCode="italics">Susceptible</content> indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of <content styleCode="italics">Intermediate</content> indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of <content styleCode="italics">Resistant</content> indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected. </paragraph>
                        <paragraph>
                           <content styleCode="bold">            Quality Control:<br/>
                           </content>Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test<sup>.1,2,3,4</sup> Standard levofloxacin powder should provide the range of MIC values noted in <content styleCode="bold">Table 10</content>. For the diffusion technique using the 5 mcg disk, the criteria in <content styleCode="bold">Table 10 </content>should be achieved.</paragraph>
                        <table>
                           <caption>Table 10: Quality Control Ranges for Susceptibility Testing</caption>
                           <col width="7cm"/>
                           <col width="134.7pt"/>
                           <col width="4cm"/>
                           <col width="92.1pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Microorganism</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Microorganism<br/>QC Number</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">MIC (mcg/mL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Disk Diffusion<br/>(zone diameter in mm)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Enterococcus faecalis</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 29212</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>0.25 – 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>--</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Escherichia coli</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 25922</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>0.008 – 0.06</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>29 – 37</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Escherichia coli</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 35218</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>0.015 – 0.06</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>--</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Haemophilus influenzae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 49247</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>0.008 – 0.03</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>32 – 40</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Pseudomonas aeruginosa</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 27853</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>0.5 – 4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>19 – 26</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Staphylococcus aureus</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 29213</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>0.06 – 0.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>--</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Staphylococcus aureus</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 25923</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>--</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>25 – 30</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>
                                       <content styleCode="italics">Streptococcus pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>ATCC 49619</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>0.5 – 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     " valign="top">
                                    <paragraph>20 – 25</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20160816"/>
                     <excerpt>
                        <highlight>
                           <text>
                              <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria (<linkHtml href="#LINK_a7b84a38-d1da-4248-8f0b-6cc263a3ba3e">1.15</linkHtml>).</paragraph>
                           </text>
                        </highlight>
                     </excerpt>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_17d4e9cd-7b7f-4bc1-9322-9c34024eea7b">
               <id root="177fa98e-3531-4d2b-8968-3eba711f5dd4"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20160815"/>
               <component>
                  <section ID="LINK_808a0b7e-82d1-4e86-a48b-49a6a789972e">
                     <id root="c86e868d-78f2-40cb-abfc-16f62a6ad604"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>In a lifetime bioassay in rats, levofloxacin exhibited no carcinogenic potential following daily dietary administration for 2 years; the highest dose (100 mg/kg/day<content styleCode="italics">) </content>was 1.4 times the highest recommended human dose (750 mg) based upon relative body surface area. Levofloxacin did not shorten the time to tumor development of UV-induced skin tumors in hairless albino (Skh-1) mice at any levofloxacin dose level and was therefore not photo-carcinogenic under conditions of this study. Dermal levofloxacin concentrations in the hairless mice ranged from 25 to 42 mcg/g at the highest levofloxacin dose level (300 mg/kg/day) used in the photo-carcinogenicity study. By comparison, dermal levofloxacin concentrations in human subjects receiving 750 mg of levofloxacin averaged approximately 11.8 mcg/g at C<sub>max</sub>.</paragraph>
                        <paragraph>Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay (<content styleCode="italics">S. typhimurium</content> and <content styleCode="italics">E. coli)</content>, CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA synthesis assay, and the mouse sister chromatid exchange assay. It was positive in the <content styleCode="italics">in vitro</content> chromosomal aberration (CHL cell line) and sister chromatid exchange (CHL/IU cell line) assays.</paragraph>
                        <paragraph>Levofloxacin caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day, corresponding to 4.2 times the highest recommended human dose based upon relative body surface area and intravenous doses as high as 100 mg/kg/day, corresponding to 1.2 times the highest recommended human dose based upon relative body surface area.</paragraph>
                     </text>
                     <effectiveTime value="20141007"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5db87c74-a8b2-48e6-84c5-01dd8fb44315">
                     <id root="27d41bab-5f79-4fdf-97d6-c0ea21ad0180"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>
                        <content styleCode="bold">13.2 Animal Toxicology and/or Pharmacology</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.11</linkHtml>)</content>]. In immature dogs (4–5 months old), oral doses of 10 mg/kg/day for 7 days and intravenous doses of 4 mg/kg/day for 14 days of levofloxacin resulted in arthropathic lesions. Administration at oral doses of 300 mg/kg/day for 7 days and intravenous doses of 60 mg/kg/day for 4 weeks produced arthropathy in juvenile rats. Three-month old beagle dogs dosed orally with levofloxacin at 40 mg/kg/day exhibited clinically severe arthrotoxicity resulting in the termination of dosing at Day 8 of a 14-day dosing routine. Slight musculoskeletal clinical effects, in the absence of gross pathological or histopathological effects, resulted from the lowest dose level of 2.5 mg/‌kg/day (approximately 0.2-fold the pediatric dose based upon AUC comparisons). Synovitis and articular cartilage lesions were observed at the 10 and 40 mg/kg dose levels (approximately 0.7-fold and 2.4-fold the pediatric dose, respectively, based on AUC comparisons). Articular cartilage gross pathology and histopathology persisted to the end of the 18-week recovery period for those dogs from the 10 and 40 mg/kg/day dose levels.</paragraph>
                        <paragraph>When tested in a mouse ear swelling bioassay, levofloxacin exhibited phototoxicity similar in magnitude to ofloxacin, but less phototoxicity than other quinolones.</paragraph>
                        <paragraph>While crystalluria has been observed in some intravenous rat studies, urinary crystals are not formed in the bladder, being present only after micturition and are not associated with nephrotoxicity.</paragraph>
                        <paragraph>In mice, the CNS stimulatory effect of quinolones is enhanced by concomitant administration of non-steroidal anti‑inflammatory drugs.</paragraph>
                        <paragraph>In dogs, levofloxacin administered at 6 mg/kg or higher by rapid intravenous injection produced hypotensive effects. These effects were considered to be related to histamine release.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> and <content styleCode="italics">in vivo</content> studies in animals indicate that levofloxacin is neither an enzyme inducer nor inhibitor in the human therapeutic plasma concentration range; therefore, no drug metabolizing enzyme-related interactions with other drugs or agents are anticipated.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4ef60d23-9b54-4faa-a092-111267f448ff">
               <id root="52941be3-c279-4405-8274-422fc67239b8"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20160816"/>
               <component>
                  <section ID="LINK_20b92eae-b505-4e25-a012-6b7ea12bab25">
                     <id root="88340845-d19a-4af5-8ae3-d3db74a56a59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1 Nosocomial Pneumonia</content>
                     </title>
                     <text>
                        <paragraph>Adult patients with clinically and radiologically documented nosocomial pneumonia were enrolled in a multicenter, randomized, open-label study comparing intravenous levofloxacin (750 mg once daily) followed by oral levofloxacin (750 mg once daily) for a total of 7–15 days to intravenous imipenem/cilastatin (500–1000 mg every 6–8 hours daily) followed by oral ciprofloxacin (750 mg every 12 hours daily) for a total of 7–15 days. Levofloxacin-treated patients received an average of 7 days of intravenous therapy (range: 1–16 days); comparator-treated patients received an average of 8 days of intravenous therapy (range: 1–19 days).</paragraph>
                        <paragraph>Overall, in the clinically and microbiologically evaluable population, adjunctive therapy was empirically initiated at study entry in 56 of 93 (60.2%) patients in the levofloxacin arm and 53 of 94 (56.4%) patients in the comparator arm. The average duration of adjunctive therapy was 7 days in the levofloxacin arm and 7 days in the comparator. In clinically and microbiologically evaluable patients with documented <content styleCode="italics">Pseudomonas aeruginosa </content>infection, 15 of 17 (88.2%) received ceftazidime (N = 11) or piperacillin/tazobactam (N = 4) in the levofloxacin arm and 16 of 17 (94.1%) received an aminoglycoside in the comparator arm. Overall, in clinically and microbiologically evaluable patients, vancomycin was added to the treatment regimen of 37 of 93 (39.8%) patients in the levofloxacin arm and 28 of 94 (29.8%) patients in the comparator arm for suspected methicillin-resistant <content styleCode="italics">S. aureus </content>infection.</paragraph>
                        <paragraph>Clinical success rates in clinically and microbiologically evaluable patients at the posttherapy visit (primary study endpoint assessed on day 3–15 after completing therapy) were 58.1% for levofloxacin and 60.6% for comparator. The 95% CI for the difference of response rates (levofloxacin minus comparator) was [-17.2, 12.0]. The microbiological eradication rates at the posttherapy visit were 66.7% for levofloxacin and 60.6% for comparator. The 95% CI for the difference of eradication rates (levofloxacin minus comparator) was [-8.3, 20.3]. Clinical success and microbiological eradication rates by pathogen are detailed in <content styleCode="bold">Table 11</content>
                        </paragraph>
                        <table>
                           <caption>Table 11: Clinical Success Rates and Bacteriological Eradication Rates (Nosocomial Pneumonia)</caption>
                           <col width="3cm"/>
                           <col width="1cm"/>
                           <col width="7cm"/>
                           <col width="1cm"/>
                           <col width="7cm"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Pathogen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Levofloxacin No. (%) of Patients Microbiologic/Clinical Outcomes</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Imipenem/Cilastatin No. (%) of Patients Microbiologic/Clinical Outcomes</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>MSSA<footnote ID="FOOT_9328">Methicillin-susceptible <content styleCode="italics">S. aureus</content>
                                       </footnote> </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>21</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>14 (66.7)/13 (61.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>19</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>13 (68.4)/15 (78.9)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">P. aeruginosa<footnote ID="FOOT_9329">See above text for use of combination therapy</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>10 (58.8)/11 (64.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5 (29.4)/7 (41.2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">S. marcescens </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>9 (81.8)/7 (63.6)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>2 (28.6)/3 (42.9)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">E. coli </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>10 (83.3)/7 (58.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7 (63.6 )/8 (72.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">K. pneumoniae<footnote ID="FOOT_9330">The observed differences in rates for the clinical and microbiological outcomes may reflect other factors that were not accounted for in the study</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>9 (81.8)/5 (45.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>6 (85.7)/3 (42.9)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">H. influenzae </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>16</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>13 (81.3)/10 (62.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>14 (93.3)/11 (73.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">S. pneumoniae </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>3 (75.0)/3 (75.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>5 (71.4)/4 (57.1)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7bfbeeef-706d-4728-951a-d82fe51742c1">
                     <id root="d5634fb2-bda4-4c18-b214-7737022cb523"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>Adult inpatients and outpatients with a diagnosis of community-acquired bacterial pneumonia were evaluated in 2 pivotal clinical studies. In the first study, 590 patients were enrolled in a prospective, multi-center, unblinded randomized trial comparing levofloxacin 500 mg once daily orally or intravenously for 7 to 14 days to ceftriaxone 1 to 2 grams intravenously once or in equally divided doses twice daily followed by cefuroxime axetil 500 mg orally twice daily for a total of 7 to 14 days. Patients assigned to treatment with the control regimen were allowed to receive erythromycin (or doxycycline if intolerant of erythromycin) if an infection due to atypical pathogens was suspected or proven. Clinical and microbiologic evaluations were performed during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Clinical success (cure plus improvement) with levofloxacin at 5 to 7 days posttherapy, the primary efficacy variable in this study, was superior (95%) to the control group (83%). The 95% CI for the difference of response rates (levofloxacin minus comparator) was [-6, 19]. In the second study, 264 patients were enrolled in a prospective, multi-center, non-comparative trial of 500 mg levofloxacin administered orally or intravenously once daily for 7 to 14 days. Clinical success for clinically evaluable patients was 93%. For both studies, the clinical success rate in patients with atypical pneumonia due to <content styleCode="italics">Chlamydophila pneumoniae, Mycoplasma pneumoniae</content>, and <content styleCode="italics">Legionella pneumophila</content> were 96%, 96%, and 70%, respectively. Microbiologic eradication rates across both studies are presented in <content styleCode="bold">Table 12</content>.</paragraph>
                        <table>
                           <caption>Table 12: Bacteriological Eradication Rates Across 2 Community Acquired Pneumonia Clinical Studies</caption>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Pathogen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">No. Pathogens</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Bacteriological Eradication Rate (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">H. influenzae </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>55</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>98</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">S. pneumoniae </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>83</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>95</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">S. aureus </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>88</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">M. catarrhalis </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>94</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">H. parainfluenzae </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>19</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>95</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">K. pneumoniae </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>100.0</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Community-Acquired Pneumonia Due to Multi-Drug Resistant <content styleCode="italics">Streptococcus pneumoniae<br/>
                              </content>
                           </content>Levofloxacin was effective for the treatment of community-acquired pneumonia caused by multi-drug resistant <content styleCode="italics">Streptococcus pneumoniae </content>(MDRSP). MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC ≥ 2 mcg/mL), 2<sup>nd</sup> generation cephalosporins (e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole). Of 40 microbiologically evaluable patients with MDRSP isolates, 38 patients (95.0%) achieved clinical and bacteriologic success at post-therapy. The clinical and bacterial success rates are shown in <content styleCode="bold">Table 13</content>.</paragraph>
                        <table>
                           <caption>Table 13: Clinical and Bacterial Success Rates for Levofloxacin-Treated MDRSP in Community Acquired Pneumonia Patients (Population Valid for Efficacy)</caption>
                           <col width="205.55pt"/>
                           <col width="83.25pt"/>
                           <col width="86.85pt"/>
                           <col width="79.7pt"/>
                           <col width="83.3pt"/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Screening Susceptibility</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Clinical Success</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Bacteriological Success<footnote ID="FOOT_9331">One patient had a respiratory isolate that was resistant to tetracycline, cefuroxime, macrolides and TMP/SMX and intermediate to penicillin and a blood isolate that was intermediate to penicillin and cefuroxime and resistant to the other classes. The patient is included in the database based on respiratory isolate.</footnote> </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">n/N<footnote ID="FOOT_9332">n = the number of microbiologically evaluable patients who were clinical successes; N = number of microbiologically evaluable patients in the designated resistance group.</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">n/N<footnote ID="FOOT_9333">n = the number of MDRSP isolates eradicated or presumed eradicated in microbiologically evaluable patients; N = number of MDRSP isolates in a designated resistance group.</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Penicillin-resistant </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>16/17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>94.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>16/17</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>94.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>2<sup>nd</sup> generation Cephalosporin resistant</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>31/32</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>96.9</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>31/32</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>96.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Macrolide-resistant </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>28/29</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>96.6</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>28/29</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>96.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Trimethoprim/ Sulfamethoxazole resistant</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>17/19</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>89.5</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>17/19</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>89.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Tetracycline-resistant </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>12/12</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>100</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>12/12</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>100</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Not all isolates were resistant to all antimicrobial classes tested. Success and eradication rates are summarized in <content styleCode="bold">Table 14</content>.</paragraph>
                        <table>
                           <caption>Table 14: Clinical Success and Bacteriologic Eradication Rates for Resistant Streptococcus pneumoniae
(Community Acquired Pneumonia)</caption>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Type of Resistance</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Clinical Success</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Bacteriologic Eradication</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Resistant to 2 antibacterials</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>17/18 (94.4%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>17/18 (94.4%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Resistant to 3 antibacterials</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>14/15 (93.3%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>14/15 (93.3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Resistant to 4 antibacterials</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7/7 (100%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>7/7 (100%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Resistant to 5 antibacterials</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>Bacteremia with MDRSP </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>8/9 (89%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>8/9 (89%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d37e1bfb-e002-4c81-883d-58e722a52a65">
                     <id root="2c137cf1-79b0-4989-8e4b-46ba8ff665ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.3 Community-Acquired Pneumonia: 5-Day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>To evaluate the safety and efficacy of the higher dose and shorter course of levofloxacin, 528 outpatient and hospitalized adults with clinically and radiologically determined mild to severe community-acquired pneumonia were evaluated in a double-blind, randomized, prospective, multicenter study comparing levofloxacin 750 mg, IV or orally, every day for five days or levofloxacin 500 mg IV or orally, every day for 10 days.</paragraph>
                        <paragraph>Clinical success rates (cure plus improvement) in the clinically evaluable population were 90.9% in the levofloxacin 750 mg group and 91.1% in the levofloxacin 500 mg group. The 95% CI for the difference of response rates (levofloxacin 750 minus levofloxacin 500) was [-5.9, 5.4]. In the clinically evaluable population (31–38 days after enrollment) pneumonia was observed in 7 out of 151 patients in the levofloxacin 750 mg group and 2 out of 147 patients in the levofloxacin 500 mg group. Given the small numbers observed, the significance of this finding cannot be determined statistically. The microbiological efficacy of the 5-day regimen was documented for infections listed in <content styleCode="bold">Table 15</content>.</paragraph>
                        <table>
                           <caption>Table 15: Bacteriological Eradication Rates (Community-Acquired Pneumonia)</caption>
                           <col width="269.3pt"/>
                           <col width="269.35pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">S. pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>19/20 (95%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Haemophilus influenzae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>12/12 (100%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Haemophilus parainfluenzae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>10/10 (100%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Mycoplasma pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>26/27 (96%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Chlamydophila pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>13/15 (87%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_48f57bf0-9a7c-4dd5-b0da-db93a6a42881">
                     <id root="7ca4800b-fd0b-4276-9520-1ec21b129d09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.4 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin is approved for the treatment of acute bacterial sinusitis (ABS) using either 750 mg by mouth × 5 days or 500 mg by mouth once daily × 10–14 days. To evaluate the safety and efficacy of a high dose short course of levofloxacin, 780 outpatient adults with clinically and radiologically determined acute bacterial sinusitis were evaluated in a double‑blind, randomized, prospective, multicenter study comparing levofloxacin 750 mg by mouth once daily for five days to levofloxacin 500 mg by mouth once daily for 10 days.</paragraph>
                        <paragraph>Clinical success rates (defined as complete or partial resolution of the pre-treatment signs and symptoms of ABS to such an extent that no further antibiotic treatment was deemed necessary) in the microbiologically evaluable population were 91.4% (139/152) in the levofloxacin 750 mg group and 88.6% (132/149) in the levofloxacin 500 mg group at the test-of‑cure (TOC) visit (95% CI [-4.2, 10.0] for levofloxacin 750 mg minus levofloxacin 500 mg).</paragraph>
                        <paragraph>Rates of clinical success by pathogen in the microbiologically evaluable population who had specimens obtained by antral tap at study entry showed comparable results for the five- and ten-day regimens at the test-of-cure visit 22 days post treatment (see <content styleCode="bold">Table 16</content>).</paragraph>
                        <table>
                           <caption>Table 16: Clinical Success Rate by Pathogen at the TOC in Microbiologically Evaluable Subjects Who Underwent Antral Puncture (Acute Bacterial Sinusitis)</caption>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Pathogen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Levofloxacin 750 mg × 5 days</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Levofloxacin 500 mg × 10 days</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Streptococcus pneumoniae<footnote ID="FOOT_9334">Note: Forty percent of the subjects in this trial had specimens obtained by sinus endoscopy. The efficacy data for subjects whose specimen was obtained endoscopically were comparable to those presented in the above table.</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>25/27 (92.6%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>26/27 (96.3%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Haemophilus influenzae<footnoteRef IDREF="FOOT_9334"/> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>19/21 (90.5%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>25/27 (92.6%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Moraxella catarrhalis<footnoteRef IDREF="FOOT_9334"/> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>10/11 (90.9%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>13/13 (100%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_edad6655-a3a5-44f1-8cdd-6b7dd03e58cb">
                     <id root="ef104f81-0535-408d-900f-a045bc7727dc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.5 Complicated Skin and Skin Structure Infections</content>
                     </title>
                     <text>
                        <paragraph>Three hundred ninety-nine patients were enrolled in an open-label, randomized, comparative study for complicated skin and skin structure infections. The patients were randomized to receive either levofloxacin 750 mg once daily (IV followed by oral), or an approved comparator for a median of 10 ± 4.7 days. As is expected in complicated skin and skin structure infections, surgical procedures were performed in the levofloxacin and comparator groups. Surgery (incision and drainage or debridement) was performed on 45% of the levofloxacin-treated patients and 44% of the comparator-treated patients, either shortly before or during antibiotic treatment and formed an integral part of therapy for this indication.</paragraph>
                        <paragraph>Among those who could be evaluated clinically 2–5 days after completion of study drug, overall success rates (improved or cured) were 116/138 (84.1%) for patients treated with levofloxacin and 106/132 (80.3%) for patients treated with the comparator.</paragraph>
                        <paragraph>Success rates varied with the type of diagnosis ranging from 68% in patients with infected ulcers to 90% in patients with infected wounds and abscesses. These rates were equivalent to those seen with comparator drugs.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_16b0995a-829f-4052-8d18-ca2c6c7e96aa">
                     <id root="09fe30b6-615e-4177-85af-af24921091e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.6 Chronic Bacterial Prostatitis</content>
                     </title>
                     <text>
                        <paragraph>Adult patients with a clinical diagnosis of prostatitis and microbiological culture results from urine sample collected after prostatic massage (VB<sub>3</sub>) or expressed prostatic secretion (EPS) specimens obtained via the Meares-Stamey procedure were enrolled in a multicenter, randomized, double-blind study comparing oral levofloxacin 500 mg, once daily for a total of 28 days to oral ciprofloxacin 500 mg, twice daily for a total of 28 days. The primary efficacy endpoint was microbiologic efficacy in microbiologically evaluable patients. A total of 136 and 125 microbiologically evaluable patients were enrolled in the levofloxacin and ciprofloxacin groups, respectively. The microbiologic eradication rate by patient infection at 5–18 days after completion of therapy was 75.0% in the levofloxacin group and 76.8% in the ciprofloxacin group (95% CI [-12.58, 8.98] for levofloxacin minus ciprofloxacin). The overall eradication rates for pathogens of interest are presented in <content styleCode="bold">Table 17</content>.</paragraph>
                        <table width="644px">
                           <caption>Table 17: Bacteriological Eradication Rates (Chronic Bacterial Prostatitis)</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> </td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Levofloxacin (N = 136)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Ciprofloxacin (N = 125)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="bold">Pathogen</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Eradication</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">N</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Eradication</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="italics">E. coli </content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>14 (93.3%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>9 (81.8%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="italics">E. faecalis </content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>54</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>39 (72.2%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>44</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>33 (75.0%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="italics">S. epidermidis<footnote ID="FOOT_9335">Eradication rates shown are for patients who had a sole pathogen only; mixed cultures were excluded.</footnote> </content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">9 (81.8%)</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>11 (78.6%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Eradication rates for <content styleCode="italics">S. epidermidis </content>when found with other co-pathogens are consistent with rates seen in pure isolates.</paragraph>
                        <paragraph>Clinical success (cure + improvement with no need for further antibiotic therapy) rates in microbiologically evaluable population 5–18 days after completion of therapy were 75.0% for levofloxacin-treated patients and 72.8% for ciprofloxacin-treated patients (95% CI [-8.87, 13.27] for levofloxacin minus ciprofloxacin). Clinical long-term success (24–45 days after completion of therapy) rates were 66.7% for the levofloxacin-treated patients and 76.9% for the ciprofloxacin-treated patients (95% CI [-23.40, 2.89] for levofloxacin minus ciprofloxacin).</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2ef23ab7-6006-481b-8fc4-08bca9b2655c">
                     <id root="a3c8bab9-2005-4548-8332-a9c7b5b1a74b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.7 Complicated Urinary Tract Infections and Acute Pyelonephritis: 5-day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>To evaluate the safety and efficacy of the higher dose and shorter course of levofloxacin, 1109 patients with cUTI and AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the US from November 2004 to April 2006 comparing levofloxacin 750 mg IV or orally once daily for 5 days (546 patients) with ciprofloxacin 400 mg IV or 500 mg orally twice daily for 10 days (563 patients). Patients with AP complicated by underlying renal diseases or conditions such as complete obstruction, surgery, transplantation, concurrent infection or congenital malformation were excluded. Efficacy was measured by bacteriologic eradication of the baseline organism(s) at the post-therapy visit in patients with a pathogen identified at baseline. The post-therapy (test-of-cure) visit occurred 10 to 14 days after the last active dose of levofloxacin and 5 to 9 days after the last dose of active ciprofloxacin. </paragraph>
                        <paragraph>The bacteriologic cure rates overall for levofloxacin and control at the test-of-cure (TOC) visit for the group of all patients with a documented pathogen at baseline (modified intent to treat or mITT) and the group of patients in the mITT population who closely followed the protocol (Microbiologically Evaluable) are summarized in <content styleCode="bold">Table 18</content>.</paragraph>
                        <table>
                           <caption>Table 18: Bacteriological Eradication at Test-of-Cure</caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     "> </td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">Levofloxacin</content>
                                    <br/>750 mg orally or IV once daily<br/>for 5 days</td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">Ciprofloxacin</content>
                                    <br/>400 mg IV/500 mg orally twice daily<br/>for 10 days</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">Overall Difference<br/>[95% Cl]</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">n/N</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">n/N</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">Levofloxacin - Ciprofloxacin</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="6" styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="bold">mITT Population<footnote ID="FOOT_7012">The mITT population included patients who received study medication and who had a positive (≥ 10<sup>5</sup> CFU/mL) urine culture with no more than 2 uropathogens at baseline. Patients with missing response were counted as failures in this analysis. <br/>
                                       </footnote> </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> Overall (cUTI or AP)</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">252/333</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">75.7</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">239/318</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">75.2</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">0.5 [-6.1, 7.1] </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> cUTI</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">168/230</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">73.0</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">157/213</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">73.7</td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> AP</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">84/103</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">81.6</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">82/105</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">78.1</td>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> </td>
                              </tr>
                              <tr>
                                 <td align="center" colspan="6" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold"> Microbiological Evaluable Population<footnote ID="FOOT_7013">The Microbiologically Evaluable population included patients with a confirmed diagnosis of cUTI or AP, a causative organism(s) at baseline present at ≥ 10<sup>5</sup> CFU/mL, a valid test-of-cure urine culture, no pathogen isolated from blood resistant to study drug, no premature discontinuation or loss to follow-up, and compliance with treatment (among other criteria).</footnote> </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> Overall (cUTI or AP)</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">228/265</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">86.0</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">215/241</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">89.2</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">-3.2 [-8.9, 2.5] </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> cUTI</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">154/185</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">83.2</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">144/165</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">87.3</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> AP</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">74/80</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">92.5</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">71/76</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">93.4</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Microbiologic eradication rates in the Microbiologically Evaluable population at TOC for individual pathogens recovered from patients randomized to levofloxacin treatment are presented in <content styleCode="bold">Table 19</content>.</paragraph>
                        <table>
                           <caption>Table 19: Bacteriological Eradication Rates for Individual Pathogens Recovered From Patients Randomized to Levofloxacin 750 mg QD for 5 Days Treatment</caption>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <col width="179.55pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Pathogen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">Bacteriological Eradication Rate<br/>(n/N)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Escherichia coli<footnote ID="FOOT_9338">The predominant organism isolated from patients with AP was <content styleCode="italics">E. coli</content>: 91% (63/69) eradication in AP and 89% (92/103) in patients with cUTI.</footnote> </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>155/172</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>90</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Klebsiella pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>20/23</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>87</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>
                                       <content styleCode="italics">Proteus mirabilis</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>12/12</paragraph>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <paragraph>100</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f00de8b2-e8fa-4e23-aaa7-36a8a642f8fb">
                     <id root="9999bf58-868a-422c-8d8c-4af37ec4588b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.8 Complicated Urinary Tract Infections and Acute Pyelonephritis: 10-day Treatment Regimen</content>
                     </title>
                     <text>
                        <paragraph>To evaluate the safety and efficacy of the 250 mg dose, 10 day regimen of levofloxacin, 567 patients with uncomplicated UTI, mild-to-moderate cUTI, and mild-to-moderate AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the US from June 1993 to January 1995 comparing levofloxacin 250 mg orally once daily for 10 days (285 patients) with ciprofloxacin 500 mg orally twice daily for 10 days (282 patients). Patients with a resistant pathogen, recurrent UTI, women over age 55 years, and with an indwelling catheter were initially excluded, prior to protocol amendment which took place after 30% of enrollment. Microbiological efficacy was measured by bacteriologic eradication of the baseline organism(s) at 1–12 days post-therapy in patients with a pathogen identified at baseline.</paragraph>
                        <paragraph>The bacteriologic cure rates overall for levofloxacin and control at the test-of-cure (TOC) visit for the group of all patients with a documented pathogen at baseline (modified intent to treat or mITT) and the group of patients in the mITT population who closely followed the protocol (Microbiologically Evaluable) are summarized in <content styleCode="bold">Table 20</content>.</paragraph>
                        <table>
                           <caption>Table 20: Bacteriological Eradication Overall (cUTI or AP) at Test-Of-Cure<footnote ID="FOOT_7014">1–9 days posttherapy for 30% of subjects enrolled prior to a protocol amendment; 5–12 days posttherapy for 70% of subjects.</footnote>  </caption>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     "> </td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="bold">Levofloxacin<br/>
                                    </content>250 mg once daily for 10 days</td>
                                 <td align="center" colspan="2" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">Ciprofloxacin<br/>
                                    </content>500 mg twice daily for 10 days </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="bold">n/N</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="bold">n/N</content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold">%</content> </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     "> <content styleCode="bold">mITT Population<footnote ID="FOOT_7015">The mITT population included patients who had a pathogen isolated at baseline. Patients with missing response were counted as failures in this analysis.</footnote> </content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">174/209 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> 83.3</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> 184/219</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     ">84.0 </td>
                              </tr>
                              <tr>
                                 <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                                    <content styleCode="bold"> Microbiologically Evaluable Population<footnote ID="FOOT_7016">The Microbiologically Evaluable population included mITT patients who met protocol-specified evaluability criteria.</footnote> </content>
                                 </td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> 164/177</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> 92.7</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> 159/171</td>
                                 <td align="center" styleCode="     Botrule          Toprule         Lrule          Rrule     "> 93.0</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20160816"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_eda5db73-92cb-4927-9490-0ee79d298e57">
                     <id root="1245202d-9e8f-4698-8e7c-e88e49a1632b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.9 Inhalational Anthrax (Post-Exposure)</content>
                     </title>
                     <text>
                        <paragraph>The effectiveness of levofloxacin for this indication is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The mean plasma concentrations of levofloxacin associated with a statistically significant improvement in survival over placebo in the rhesus monkey model of inhalational anthrax are reached or exceeded in adult and pediatric patients receiving the recommended oral and intravenous dosage regimens [see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_c6c7d68d-c7d3-4be1-94e6-45436f186678">1.13</linkHtml> )</content>; <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">2.1</linkHtml>, <linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>)</content>].</paragraph>
                        <paragraph>Levofloxacin pharmacokinetics have been evaluated in adult and pediatric patients. The mean (± SD) steady state peak plasma concentration in human adults receiving 500 mg orally or intravenously once daily is 5.7 ± 1.4 and 6.4 ± 0.8 mcg/‌mL, respectively; and the corresponding total plasma exposure (AUC<sub>0-24</sub>) is 47.5 ± 6.7 and 54.6 ± 11.1 mcg.h/mL, respectively. The predicted steady-state pharmacokinetic parameters in pediatric patients ranging in age from 6 months to 17 years receiving 8 mg/kg orally every 12 hours (not to exceed 250 mg per dose) were calculated to be comparable to those observed in adults receiving 500 mg orally once daily [see <content styleCode="bold">CLINICAL PHARMACOLOGY (<linkHtml href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</linkHtml>)</content>].</paragraph>
                        <paragraph>In adults, the safety of levofloxacin for treatment durations of up to 28 days is well characterized. However, information pertaining to extended use at 500 mg daily up to 60 days is limited. Prolonged levofloxacin therapy in adults should only be used when the benefit outweighs the risk.</paragraph>
                        <paragraph>In pediatric patients, the safety of levofloxacin for treatment durations of more than 14 days has not been studied. An increased incidence of musculoskeletal adverse events (arthralgia, arthritis, tendinopathy, gait abnormality) compared to controls has been observed in clinical studies with treatment duration of up to 14 days. Long-term safety data, including effects on cartilage, following the administration of levofloxacin to pediatric patients is limited [see <content styleCode="bold">WARNINGS AND PRECAUTIONS (<linkHtml href="#LINK_550c6231-6cb2-42e4-9049-2c1d5afddcab">5.10</linkHtml>)</content>; <content styleCode="bold">USE IN SPECIFIC POPULATIONS (<linkHtml href="#LINK_2de9de63-7015-4729-94e1-92c1738623fa">8.4</linkHtml>)</content>].</paragraph>
                        <paragraph>A placebo-controlled animal study in rhesus monkeys exposed to an inhaled mean dose of 49 LD<sub>50</sub> (~2.7 x 10<sup>6</sup>) spores (range 17 - 118 LD<sub>50</sub>) of <content styleCode="italics">B. anthracis </content>(Ames strain) was conducted. The minimal inhibitory concentration (MIC) of levofloxacin for the anthrax strain used in this study was 0.125 mcg/mL. In the animals studied, mean plasma concentrations of levofloxacin achieved at expected T<sub>max</sub> (1 hour post-dose) following oral dosing to steady state ranged from 2.79 to 4.87 mcg/mL. Steady state trough concentrations at 24 hours post-dose ranged from 0.107 to 0.164 mcg/‌mL. Mean (SD) steady state AUC<sub>0-24</sub> was 33.4 ± 3.2 mcg.h/mL (range 30.4 to 36.0 mcg.h/mL). Mortality due to anthrax for animals that received a 30 day regimen of oral levofloxacin beginning 24 hrs post exposure was significantly lower (1/10), compared to the placebo group (9/10) [P = 0.0011, 2-sided Fisher’s Exact Test]. The one levofloxacin treated animal that died of anthrax did so following the 30-day drug administration period.</paragraph>
                     </text>
                     <effectiveTime value="20130801"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_61466cb7-0624-4e2a-8190-17b69bbd3bfb">
                     <id root="a174f061-8458-435b-83f6-ed3913b9dfc1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.10 Plague</content>
                     </title>
                     <text>
                        <paragraph>Efficacy studies of levofloxacin could not be conducted in humans with pneumonic plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals. </paragraph>
                        <paragraph>The mean plasma concentrations of levofloxacin associated with a statistically significant improvement in survival over placebo in an African green monkey model of pneumonic plague are reached or exceeded in adult and pediatric patients receiving the recommended oral and intravenous dosage regimens [see <content styleCode="bold">INDICATIONS AND USAGE (<linkHtml href="#LINK_0d91e8dc-a950-4bdd-92b8-b2629df2dbb3">1.14</linkHtml>)</content>; <content styleCode="bold">DOSAGE AND ADMINISTRATION (<linkHtml href="#LINK_d3ea19ca-1e35-40d0-8e9b-37c2e8a4a0d8">2.1</linkHtml>)</content>,<content styleCode="bold"> (<linkHtml href="#LINK_074c7e76-37c8-48ae-bf26-f7ff41b1d00b">2.2</linkHtml>)</content>]. </paragraph>
                        <paragraph>Levofloxacin pharmacokinetics have been evaluated in adult and pediatric patients. The mean (± SD) steady state peak plasma concentration in human adults receiving 500 mg orally or intravenously once daily is 5.7 ± 1.4 and 6.4 ± 0.8 mcg/mL, respectively; and the corresponding total plasma exposure (AUC<sub>0-24</sub>) is 47.5 ± 6.7 and 54.6 ± 11.1 mcg.h/mL, respectively. The predicted steady-state pharmacokinetic parameters in pediatric patients ranging in age from 6 months to 17 years receiving 8 mg/kg orally every 12 hours (not to exceed 250 mg per dose) were calculated to be comparable to those observed in adults receiving 500 mg orally once daily [see <content styleCode="bold">CLINICAL PHARMACOLOGY (<linkHtml href="#LINK_a0e3b629-b55b-404c-9c1a-02bf5af9d7ec">12.3</linkHtml>)</content>]. </paragraph>
                        <paragraph>A placebo-controlled animal study in African green monkeys exposed to an inhaled mean dose of 65 LD<sub>50</sub> (range 3 to 145 LD<sub>50</sub>) of <content styleCode="italics">Yersinia pestis </content>(CO92 strain) was conducted. The minimal inhibitory concentration (MIC) of levofloxacin for the <content styleCode="italics">Y. pestis </content>strain used in this study was 0.03 mcg/mL. Mean plasma concentrations of levofloxacin achieved at the end of a single 30-min infusion ranged from 2.84 to 3.50 mcg/mL in African green monkeys. Trough concentrations at 24 hours post-dose ranged from &lt; 0.03 to 0.06 mcg/mL. Mean (SD) AUC<sub>0-24 </sub>was 11.9 (3.1) mcg.h/mL (range 9.50 to 16.86 mcg.h/mL). Animals were randomized to receive either a 10-day regimen of IV levofloxacin or placebo beginning within 6 hrs of the onset of telemetered fever (≥ 39<sup>o</sup>C for more than 1 hour). Mortality in the levofloxacin group was significantly lower (1/17) compared to the placebo group (7/7) [p &lt; 0.001, Fisher’s Exact Test; exact 95% confidence interval (-99.9%, -55.5%) for the difference in mortality]. One levofloxacin-treated animal was euthanized on Day 9 post-exposure to <content styleCode="italics">Y. pestis </content>due to a gastric complication; it had a blood culture positive for <content styleCode="italics">Y. pestis </content>on Day 3 and all subsequent daily blood cultures from Day 4 through Day 7 were negative.</paragraph>
                     </text>
                     <effectiveTime value="20160505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ef22eaa2-7142-43a1-8455-da7d368f393d">
               <id root="41b4aa84-2b92-46b3-add3-68b24edf9e3c"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <list listType="ordered" styleCode="Arabic">
                     <item>
                        <paragraph>Clinical and Laboratory Standards Institute (CLSI). <content styleCode="underline">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</content>. Approved Standard – 9<sup>th</sup> ed. CLSI Document M7-A9, CLSI, 950 West Valley Rd., Suite 2500, Wayne, PA, 2012.</paragraph>
                     </item>
                     <item>
                        <paragraph>CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 22<sup>nd </sup>Informational Supplement. CLSI Document M100 – S22, 2012.</paragraph>
                     </item>
                     <item>
                        <paragraph>CLSI Performance Standards for Antimicrobial Disk Susceptibility Tests. Approved Standard – 11<sup>th </sup>ed. CLSI M2-A11, 2012.</paragraph>
                     </item>
                     <item>
                        <paragraph>CLSI. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline – 2<sup>nd </sup>ed. CLSI Document M45-A2, 2010. </paragraph>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20160815"/>
            </section>
         </component>
         <component>
            <section ID="LINK_dd887705-9ac2-46cb-9de4-1970f5ede59c">
               <id root="bd099792-00ab-447c-b50d-bd747abd7a21"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <effectiveTime value="20141007"/>
               <component>
                  <section ID="LINK_d4d1374c-b186-4dc8-b5d6-1c8891174418">
                     <id root="aa247934-6c1a-49cd-bae4-b52d4a5d652f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">16.1 Levofloxacin Injection Premixed Solution, Single Dose in Flexible Container</content>
                     </title>
                     <text>
                        <paragraph>Levofloxacin Injection in 5% Dextrose is supplied as a single dose, premixed solution in flexible containers. Each bag contains a dilute solution with the equivalent of 250, 500, or 750 mg of levofloxacin, respectively, in 5% Dextrose (D5W).</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>50 mL fill (NDC 0143-9722-01), Cartons of 24 (NDC 0143-9722-24) 

</item>
                           <item>100 mL fill (NDC 0143-9721-01), Cartons of 24 (NDC 0143-9721-24) 

</item>
                           <item>150 mL fill (NDC 0143-9720-01), Cartons of 24 (NDC 0143-9720-24)</item>
                        </list>
                        <paragraph>Levofloxacin Injection Premix in Flexible Containers should be stored at or below 25°C (77°F); however, brief exposure up to 40°C (104°F) does not adversely affect the product. Avoid excessive heat and protect from freezing and light. Levofloxacin Injection Premix in Flexible Containers is manufactured by Hikma Farmacêutica (Portugal), S.A. and distributed by West-Ward Pharmaceutical Corp. </paragraph>
                     </text>
                     <effectiveTime value="20141007"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_21f9b8f0-53d0-4958-8d02-627a67f665dd">
               <id root="8120b67b-caa5-41b0-aac6-51fbc0bb3e14"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the <content styleCode="bold">FDA-Approved Medication Guide</content>
                     <content styleCode="bold"> (<linkHtml href="#LINK_489f6129-c614-4355-8e2d-a1d36f07fd48">17.6</linkHtml>).</content>
                  </paragraph>
               </text>
               <effectiveTime value="20160815"/>
               <component>
                  <section ID="LINK_f3cddc7b-8634-4f54-85b2-759ba7e5587c">
                     <id root="1757afb3-04f2-4ffd-81c8-7de4eb96d260"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Serious Adverse Reactions</title>
                     <text>
                        <paragraph>Advise patients to stop taking levofloxacin if they experience an adverse reaction and to call their healthcare provider for advice on completing the full course of treatment with another antibacterial drug.</paragraph>
                        <paragraph>Inform patients of the following serious adverse reactions that have been associated with levofloxacin or other fluoroquinolone use:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold">Disabling and Potentially Irreversible Serious Adverse Reactions That May Occur Together: </content>Inform patients that disabling and potentially irreversible serious adverse reactions, including tendinitis and tendon rupture, peripheral neuropathies, and central nervous system effects, have been associated with use of levofloxacin and may occur together in the same patient. Inform patients to stop taking levofloxacin immediately if they experience an adverse reaction and to call their healthcare provider.</item>
                           <item>
                              <content styleCode="bold">Tendinitis and Tendon Rupture:</content> Instruct patients to contact their healthcare provider if they experience pain, swelling, or inflammation of a tendon, or weakness or inability to use one of their joints; rest and refrain from exercise; and discontinue levofloxacin treatment. Symptoms may be irreversible. The risk of severe tendon disorder with fluoroquinolones is higher in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.</item>
                           <item>
                              <content styleCode="bold">Peripheral Neuropathies:</content> Inform patients that peripheral neuropathies have been associated with levofloxacin use, symptoms may occur soon after initiation of therapy and may be irreversible. If symptoms of peripheral neuropathy including pain, burning, tingling, numbness and/or weakness develop, immediately discontinue levofloxacin and tell them to contact their physician.</item>
                           <item>
                              <content styleCode="bold">Central Nervous System Effects</content> (for example, convulsions, dizziness, lightheadedness, increased intracranial pressure)<content styleCode="bold">:</content> Inform patients that convulsions have been reported in patients receiving fluoroquinolones, including levofloxacin. Instruct patients to notify their physician before taking this drug if they have a history of convulsions. Inform patients that they should know how they react to levofloxacin before they operate an automobile or machinery or engage in other activities requiring mental alertness and coordination. Instruct patients to notify their physician if persistent headache with or without blurred vision occurs.</item>
                           <item>
                              <content styleCode="bold">Exacerbation of Myasthenia Gravis:</content> Instruct patients to inform their physician of any history of myasthenia gravis. Instruct patients to notify their physician if they experience any symptoms of muscle weakness, including respiratory difficulties.</item>
                           <item>
                              <content styleCode="bold">Hypersensitivity Reactions:</content> Inform patients that levofloxacin can cause hypersensitivity reactions, even following a single dose, and to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (for example, swelling of the lips, tongue, face, tightness of the throat, hoarseness), or other symptoms of an allergic reaction.</item>
                           <item>
                              <content styleCode="bold">Hepatotoxicity:</content> Inform patients that severe hepatotoxicity (including acute hepatitis and fatal events) has been reported in patients taking levofloxacin. Instruct patients to inform their physician if they experience any signs or symptoms of liver injury including: loss of appetite, nausea, vomiting, fever, weakness, tiredness, right upper quadrant tenderness, itching, yellowing of the skin and eyes, light colored bowel movements or dark colored urine.</item>
                           <item>
                              <content styleCode="bold">Diarrhea:</content> Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, instruct patients to contact their physician as soon as possible.</item>
                           <item>
                              <content styleCode="bold">Prolongation of the QT Interval:</content> Instruct patients to inform their physician of any personal or family history of QT prolongation or proarrhythmic conditions such as hypokalemia, bradycardia, or recent myocardial ischemia; if they are taking any Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. Instruct patients to notify their physician if they have any symptoms of prolongation of the QT interval, including prolonged heart palpitations or a loss of consciousness.</item>
                           <item>
                              <content styleCode="bold">Musculoskeletal Disorders in Pediatric Patients:</content> Instruct parents to inform their child’s physician if the child has a history of joint-related problems before taking this drug. Inform parents of pediatric patients to notify their child’s physician of any joint-related problems that occur during or following levofloxacin therapy [see Warnings and Precautions (5.11) and Use in Specific Populations (8.4)].</item>
                           <item>
                              <content styleCode="bold">Photosensitivity/Phototoxicity:</content> Inform patients that photosensitivity/phototoxicity has been reported in patients receiving fluoroquinolones. Inform patients to minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while taking fluoroquinolones. If patients need to be outdoors while using fluoroquinolones, instruct them to wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. If a sunburn-like reaction or skin eruption occurs, instruct patients to contact their physician.</item>
                        </list>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_372f9005-d57d-43db-9534-f6fedc9f4dc7">
                     <id root="89e66201-3bc7-485a-8b4a-de0c995bbf5f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">17.2 Antibacterial Resistance</content>
                     </title>
                     <text>
                        <paragraph>Antibacterial drugs including levofloxacin should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When levofloxacin is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by levofloxacin or other antibacterial drugs in the future.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_758ffc71-e10b-4ebd-a010-25ce6bbd7f8d">
                     <id root="1d2fc0b1-da3d-4008-869c-8c29a5316d88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">17.3 Administration with Food, Fluids, and Concomitant Medications</content>
                     </title>
                     <text>
                        <paragraph>Patients should drink fluids liberally while taking levofloxacin to avoid formation of a highly concentrated urine and crystal formation in the urine.</paragraph>
                        <paragraph>Antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine should be taken at least two hours before or two hours after oral levofloxacin administration.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_59fd1e07-797c-41c8-82d3-b6597c3fddc1">
                     <id root="5272b45e-cf14-41fc-b799-884b07448077"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">17.4 Drug Interactions with Insulin, Oral Hypoglycemic Agents, and Warfarin</content>
                     </title>
                     <text>
                        <paragraph>Patients should be informed that if they are diabetic and are being treated with insulin or an oral hypoglycemic agent and a hypoglycemic reaction occurs, they should discontinue levofloxacin and consult a physician.</paragraph>
                        <paragraph>Patients should be informed that concurrent administration of warfarin and levofloxacin has been associated with increases of the International Normalized Ratio (INR) or prothrombin time and clinical episodes of bleeding. Patients should notify their physician if they are taking warfarin, be monitored for evidence of bleeding, and also have their anticoagulation tests closely monitored while taking warfarin concomitantly.</paragraph>
                     </text>
                     <effectiveTime value="20141007"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ef81fc05-e2f6-4113-906a-18fa9f8b9b66">
                     <id root="089632e7-a7a3-453a-95ca-e5e5fa83a6e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">17.5 Plague and Anthrax Studies</content>
                     </title>
                     <text>
                        <paragraph>Patients given levofloxacin for these conditions should be informed that efficacy studies could not be conducted in humans for ethical and feasibility reasons. Therefore, approval for these conditions was based on efficacy studies conducted in animals.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Manufactured by:<br/>
                           </content>HIKMA FARMACÊUTICA (PORTUGAL), S.A.<br/>Estrada do Rio da Mó, 8, 8A e 8B – Fervença – 2705-906 Terrugem SNT, PORTUGAL</paragraph>
                        <paragraph>
                           <content styleCode="bold">Distributed by:<br/>
                           </content> WEST-WARD<br/>A HIKMA COMPANY<br/>Eatontown, NJ 07724 USA</paragraph>
                        <paragraph>PIN287-WES/5<br/>Revised: August 2016</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_489f6129-c614-4355-8e2d-a1d36f07fd48">
                     <id root="ba834724-07ee-4126-b72e-2cdebef41ded"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">17.6 FDA-Approved Medication Guide</content>
                     </title>
                     <text>
                        <paragraph>.</paragraph>
                     </text>
                     <effectiveTime value="20160815"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_30147fa2-cef2-4d8e-9682-644e59c8602b">
               <id root="90b3dcb6-51e1-46c1-9d4c-fc4cc9fb3e2c"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>
                  <content styleCode="bold">MEDICATION GUIDE</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">LEVOFLOXACIN INJECTION in 5% Dextrose, Solution for Intravenous Use</content>
                  </paragraph>
                  <paragraph>Read this Medication Guide before you start taking levofloxacin. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or your treatment. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What is the most important information I should know about levofloxacin? <br/>
                     </content>
                     <content styleCode="bold">Levofloxacin, a fluoroquinolone antibiotic, can cause serious side effects. <content styleCode="bold">Some of these serious side effects can happen at the same time and could result in death.<br/>
                        </content>
                     </content>If you have any of the following serious side effects while you take levofloxacin, you should stop taking levofloxacin immediately and get medical help right away. </paragraph>
                  <paragraph>
                     <content styleCode="bold">1.    </content>
                     <content styleCode="bold">Tendon rupture or swelling of the tendon (tendinitis).</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Tendon problems can happen in people of all ages who take levofloxacin. <br/>
                        </content>Tendons are tough cords of tissue that connect muscles to bones. <br/>Some tendon problems include pain, swelling, tears, and swelling of tendons including the back of the ankle (Achilles), shoulder, hand, or other tendon sites.</item>
                     <item>
                        <content styleCode="bold">The risk of getting tendon problems while you take levofloxacin is higher if you:</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>are over 60 years of age </item>
                           <item>are taking steroids (corticosteroids) </item>
                           <item>have had a kidney, heart or lung transplant. </item>
                        </list>
                     </item>
                     <item>
                        <content styleCode="bold">Tendon problems can happen in people who do not have the above risk factors when they take levofloxacin.</content>
                     </item>
                     <item>
                        <content styleCode="bold">Other reasons that can increase your risk of tendon problems can include:</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>physical activity or exercise </item>
                           <item>kidney failure </item>
                           <item>tendon problems in the past, such as in people with rheumatoid arthritis (RA). </item>
                        </list>
                     </item>
                     <item>Stop taking levofloxacin immediately and get medical help right away at the first sign of tendon pain, swelling or inflammation. Avoid exercise and using the affected area. <br/>The most common area of pain and swelling is the Achilles tendon at the back of your ankle. This can also happen with other tendons. You may need a different antibiotic that is not a fluoroquinolone to treat your infection.</item>
                     <item>
                        <content styleCode="bold">Tendon rupture can happen while you are taking or after you have finished taking levofloxacin.</content> Tendon ruptures can happen within hours or days of taking levofloxacin and have happened up to several months after people have finished taking their fluoroquinolone. 

</item>
                     <item>
                        <content styleCode="bold">Stop taking levofloxacin immediately and get medical help right away if you get any of the following signs or symptoms of a tendon rupture:</content>
                        <list listType="unordered" styleCode="Disc">
                           <item>hear or feel a snap or pop in a tendon area 

</item>
                           <item>bruising right after an injury in a tendon area 

</item>
                           <item>unable to move the affected area or bear weight. </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">2. Changes in sensation and possible nerve damage (Peripheral Neuropathy). </content>
                  </paragraph>
                  <paragraph>Damage to the nerves in arms, hands, legs, or feet can happen in people who take fluoroquinolones, including levofloxacin. Stop taking levofloxacin immediately and talk to your healthcare provider right away if you get any of the following symptoms of peripheral neuropathy in your arms, hands, legs, or feet:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>pain</item>
                     <item>burning </item>
                     <item>tingling</item>
                     <item>numbness</item>
                     <item>weakness</item>
                  </list>
                  <paragraph>The nerve damage may be permanent.</paragraph>
                  <paragraph>
                     <content styleCode="bold">3. Central Nervous System (CNS) effects. </content>
                  </paragraph>
                  <paragraph>Seizures have been reported in people who take fluoroquinolone antibacterial medicines, including levofloxacin. Tell your healthcare provider if you have a history of seizures before you start taking levofloxacin. CNS side effects may happen as soon as after taking the first dose of levofloxacin. Stop taking levofloxacin immediately and talk to your healthcare provider right away if you get any of these side effects, or other changes in mood or behavior:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>seizures</item>
                     <item>hear voices, see things, or sense things that are not there (hallucinations)</item>
                     <item>feel restless</item>
                     <item>tremors</item>
                     <item>feel anxious or nervous</item>
                     <item>confusion</item>
                     <item>depression</item>
                     <item>trouble sleeping</item>
                     <item>nightmares</item>
                     <item>feel lightheaded or dizzy</item>
                     <item>feel more suspicious (paranoia)</item>
                     <item>suicidal thoughts or acts</item>
                     <item>headaches that will not go away, with or without blurred vision</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">4.    </content>
                     <content styleCode="bold">Worsening of myasthenia gravis (a problem that causes muscle weakness).<br/>
                     </content>Fluoroquinolones like levofloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing problems. Tell your healthcare provider if you have a history of myasthenia gravis before you start taking levofloxacin. Call your healthcare provider right away if you have any worsening muscle weakness or breathing problems.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What is levofloxacin? <br/>
                     </content>Levofloxacin is a fluoroquinolone antibiotic medicine used in adults age 18 years or older to treat certain infections caused by certain germs called bacteria. These bacterial infections include: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>nosocomial pneumonia 

</item>
                     <item>community-acquired pneumonia 

</item>
                     <item>acute sinus infection 

</item>
                     <item>acute worsening of chronic bronchitis 

</item>
                     <item>skin infections, complicated and uncomplicated 

</item>
                     <item>chronic prostate infection 

</item>
                     <item>urinary tract infections, complicated and uncomplicated 

</item>
                     <item>acute kidney infection (pyelonephritis) 

</item>
                     <item>inhalation anthrax 

</item>
                     <item>plague </item>
                  </list>
                  <paragraph>Studies of levofloxacin for use in the treatment of plague and anthrax were done in animals only, because plague and anthrax could not be studied in people.</paragraph>
                  <paragraph>Levofloxacin should not be used in patients with uncomplicated urinary tract infections, acute bacterial exacerbation of chronic bronchitis, or acute bacterial sinusitis if there are other treatment options available.</paragraph>
                  <paragraph>Levofloxacin is also used to treat children who are 6 months of age or older and may have breathed in anthrax germs, have plague, or been exposed to plague germs.</paragraph>
                  <paragraph>It is not known if levofloxacin is safe and effective in children under 6 months of age.</paragraph>
                  <paragraph>The safety and effectiveness in children treated with levofloxacin for more than 14 days is not known.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take levofloxacin? <br/>Do not take levofloxacin </content>if you have ever had a severe allergic reaction to an antibiotic known as a fluoroquinolone, or if you are allergic to any of the ingredients in levofloxacin. See the end of this leaflet for a complete list of ingredients in levofloxacin. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my healthcare provider before taking levofloxacin?<br/>Before you take levofloxacin, tell your healthcare provider if you:</content> </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>have tendon problems; levofloxacin should not be used in patients who have a history of tendon problems</item>
                     <item>have a problem that causes muscle weakness (myasthenia gravis); levofloxacin should not be used in patients who have a known history of myasthenia gravis</item>
                     <item>have central nervous system problems such as seizures (epilepsy) </item>
                     <item>have nerve problems; levofloxacin should not be used in patients who have a history of a nerve problem called peripheral neuropathy </item>
                     <item>have or anyone in your family has an irregular heartbeat, especially a condition called “QT prolongation” </item>
                     <item>have low blood potassium (hypokalemia) </item>
                     <item>have bone problems </item>
                     <item>have joint problems including rheumatoid arthritis (RA)</item>
                     <item>have kidney problems. You may need a lower dose of levofloxacin if your kidneys do not work well </item>
                     <item>have liver problems </item>
                     <item>have diabetes or problems with low blood sugar (hypoglycemia)</item>
                     <item>are pregnant or plan to become pregnant. It is not known if levofloxacin will harm your unborn child </item>
                     <item>are breastfeeding or plan to breastfeed. It is not known if levofloxacin passes into your breast milk. You and your healthcare provider should decide if you will take levofloxacin or breastfeed. You should not do both.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your healthcare provider about all the medicines you take, </content>including prescription and non-prescription medicines, vitamins, and herbal supplements. </paragraph>
                  <paragraph>Levofloxacin and other medicines can affect each other causing side effects. Especially tell your healthcare provider if you take: </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>a steroid medicine 

</item>
                     <item>an anti-psychotic medicine 

</item>
                     <item>a tricyclic antidepressant   

</item>
                     <item>a water pill (diuretic) 

</item>
                     <item>a blood thinner (warfarin, Coumadin, Jantoven) 

</item>
                     <item>an oral anti-diabetes medicine or insulin 

</item>
                     <item>an NSAID (Non-Steroidal Anti-Inflammatory Drug). Many common medicines for pain relief are NSAIDs. Taking an NSAID while you take levofloxacin or other fluoroquinolones may increase your risk of central nervous system effects and seizures. 

</item>
                     <item>theophylline (Theo-24<sup>®</sup>, Elixophyllin<sup>®</sup>, Theochron<sup>®</sup>, Uniphyl<sup>®</sup>, Theolair<sup>®</sup>) 

</item>
                     <item>a medicine to control your heart rate or rhythm (antiarrhythmics) </item>
                  </list>
                  <paragraph>Ask your healthcare provider if you are not sure if any of your medicines are listed above. </paragraph>
                  <paragraph>Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine<content styleCode="bold">. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take levofloxacin? </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Take levofloxacin exactly as your healthcare provider tells you to take it. 

</item>
                     <item>Take levofloxacin at about the same time each day. 

</item>
                     <item>Drink plenty of fluids while you take levofloxacin. 

</item>
                     <item>If you miss a dose of levofloxacin, take it as soon as you remember. Do not take more than one dose in one day. 

</item>
                     <item>Levofloxacin for Injection is given by slow intravenous (IV) infusion into your vein, over 60 or 90 minutes, as prescribed by your healthcare provider. 

</item>
                     <item>Do not skip any doses of levofloxacin or stop taking it, even if you begin to feel better, until you finish your prescribed treatment unless: 

<list listType="unordered" styleCode="Disc">
                           <item>you have tendon problems. See “<content styleCode="bold">What is the most important information I should know about levofloxacin?</content>”, 
  </item>
                           <item>you have a nerve problem. See “<content styleCode="bold">What are the possible side effects of levofloxacin?</content>”,</item>
                           <item>you have a central nervous system problem. See “<content styleCode="bold">What are the possible side effects of levofloxacin?</content>”,</item>
                           <item>you have a serious allergic reaction. See “<content styleCode="bold">What are the possible side effects of levofloxacin?</content>”. </item>
                           <item>your healthcare provider tells you to stop taking levofloxacin. </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>Taking all of your levofloxacin doses will help make sure that all of the bacteria are killed. Taking all of your levofloxacin doses will help you lower the chance that the bacteria will become resistant to levofloxacin. If your infection does not get better while you take levofloxacin, it may mean that the bacteria causing your infection may be resistant to levofloxacin. If your infection does not get better, call your healthcare provider. If your infection does not get better, levofloxacin and other similar antibiotic medicines may not work for you in the future. </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>If you take too much levofloxacin, call your healthcare provider or get medical help right away. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What should I avoid while taking levofloxacin? </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Levofloxacin can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how levofloxacin affects you. 

</item>
                     <item>Avoid sunlamps, tanning beds, and try to limit your time in the sun. Levofloxacin can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. You could get severe sunburn, blisters or swelling of your skin. If you get any of these symptoms while you take levofloxacin, call your healthcare provider right away. You should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of levofloxacin?<br/>
                     </content>
                     <content styleCode="bold">Levofloxacin can cause serious side effects, including:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>See <content styleCode="bold">"What is the most important information I should know about levofloxacin?"</content>
                     </item>
                     <item>
                        <content styleCode="bold">Serious allergic reactions:<br/>
                        </content>Allergic reactions can happen in people taking fluoroquinolones, including levofloxacin, even after only one dose. Stop taking levofloxacin and get emergency medical help right away if you have any of the following symptoms of a severe allergic reaction:</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>hives 

</item>
                     <item>trouble breathing or swallowing 

</item>
                     <item>swelling of the lips, tongue, face 

</item>
                     <item>throat tightness, hoarseness 

</item>
                     <item>rapid heartbeat 

</item>
                     <item>faint 

</item>
                     <item>skin rash</item>
                  </list>
                  <paragraph>Skin rash may happen in people taking levofloxacin, even after only one dose. Stop taking levofloxacin at the first sign of a skin rash and call your healthcare provider. Skin rash may be a sign of a more serious reaction to levofloxacin.</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Liver damage (hepatotoxicity):</content>
                        <br/>Hepatotoxicity can happen in people who take levofloxacin. Call your healthcare provider right away if you have unexplained symptoms such as:</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>nausea or vomiting 

</item>
                     <item>stomach pain 

</item>
                     <item>fever 

</item>
                     <item>weakness 

</item>
                     <item>abdominal pain or tenderness 

</item>
                     <item>itching 

</item>
                     <item>unusual tiredness 

</item>
                     <item>loss of appetite 

</item>
                     <item>light colored bowel movements 

</item>
                     <item>dark colored urine 

</item>
                     <item>yellowing of your skin or the whites of your eyes</item>
                  </list>
                  <paragraph>Stop taking levofloxacin and tell your healthcare provider right away if you have yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to levofloxacin (a liver problem).</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Intestine infection (Pseudomembranous colitis):</content>
                        <br/>Pseudomembranous colitis can happen with many antibiotics, including levofloxacin. Call your healthcare provider right away if you get watery diarrhea, diarrhea that does not go away, or bloody stools. You may have stomach cramps and a fever. Pseudomembranous colitis can happen 2 or more months after you have finished your antibiotic.</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Serious heart rhythm changes (QT prolongation and torsades de pointes):</content>
                        <br/>Tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you faint. Levofloxacin may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people:</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>who are elderly 

</item>
                     <item>with a family history of prolonged QT interval 

</item>
                     <item>with low blood potassium (hypokalemia) 

</item>
                     <item>who take certain medicines to control heart rhythm (antiarrhythmics)</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Joint Problems:</content>
                        <br/>Increased chance of problems with joints and tissues around joints in children can happen. Tell your child's healthcare provider if your child has any joint problems during or after treatment with levofloxacin.</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Changes in blood sugar:</content>
                        <br/>People who take levofloxacin and other fluoroquinolone medicines with oral anti-diabetes medicines or with insulin can get low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia). Follow your healthcare provider's instructions for how often to check your blood sugar. If you have diabetes and you get low blood sugar while taking levofloxacin, stop taking levofloxacin and call your healthcare provider right away. Your antibiotic medicine may need to be changed.</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>
                        <content styleCode="bold">Sensitivity to sunlight (photosensitivity):</content>
                        <br/>See <content styleCode="bold">"What should I avoid while taking levofloxacin?".</content>
                     </item>
                  </list>
                  <paragraph>The most common side effects of levofloxacin include:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>nausea 

</item>
                     <item>headache 

</item>
                     <item>diarrhea 

</item>
                     <item>insomnia 

</item>
                     <item>constipation 

</item>
                     <item>dizziness</item>
                  </list>
                  <paragraph>In children 6 months and older who take levofloxacin to treat anthrax disease or plague, vomiting is also common.</paragraph>
                  <paragraph>Low blood pressure can happen when levofloxacin is given too fast by IV injection. Tell your healthcare provider if you feel dizzy or faint during a treatment with levofloxacin injection.</paragraph>
                  <paragraph>Levofloxacin may cause false-positive urine screening results for opiates when testing is done with some commercially available kits. A positive result should be confirmed using a more specific test.</paragraph>
                  <paragraph>These are not all the possible side effects of levofloxacin. Tell your healthcare provider about any side effect that bothers you or that does not go away.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep levofloxacin and all medicines out of the reach of children. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of Levofloxacin<br/>
                     </content>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use levofloxacin for a condition for which it is not prescribed. Do not give levofloxacin to other people, even if they have the same symptoms that you have. It may harm them. </paragraph>
                  <paragraph>This Medication Guide summarizes the most important information about levofloxacin. If you would like more information about levofloxacin, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about levofloxacin that is written for healthcare professionals. </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in levofloxacin? </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Levofloxacin Injection Premix in Single Dose Flexible Containers: 

<list listType="unordered" styleCode="Disc">
                           <item>Active ingredient: levofloxacin. 

</item>
                           <item>Inactive ingredients: Dextrose (D5W). Solutions of hydrochloric acid and sodium hydroxide may have been added to adjust the pH. </item>
                        </list>
                     </item>
                  </list>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:<br/>
                     </content>HIKMA FARMACÊUTICA (PORTUGAL), S.A.<br/>Estrada do Rio da Mó, nº 8, 8A e 8B  – Fervença – 2705-906 Terrugem SNT, PORTUGAL</paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:<br/>
                     </content>WEST-WARD<br/>A HIKMA COMPANY<br/>Eatontown, NJ 07724 USA</paragraph>
                  <paragraph>Revised: August 2016<br/>PIN288-WES/3</paragraph>
               </text>
               <effectiveTime value="20160816"/>
            </section>
         </component>
         <component>
            <section ID="LINK_90310ca6-3f4c-4354-a4bd-ff9bea065b3c">
               <id root="580759d4-02ff-4232-aa35-c29cf4c823d9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>TO OPEN - TEAR AT NOTCH<br/>ONE UNIT<br/>
                     <content styleCode="bold">LEVOFLOXACIN INJECTION<br/>in 5% Dextrose</content>
                     <br/>
                     <content styleCode="bold">250 mg in 50 mL 5% Dextrose (5 mg/mL)<br/>FOR INTRAVENOUS INFUSION<br/>INFUSE OVER 60 MINUTES<br/>LEAVE BAG IN OVERWRAP UNTIL USE.<br/>PHARMACIST: Dispense the accompanying<br/>Medication Guide to each patient.<br/>
                     </content>Each 50 mL contains a dilute solution equivalent of 250 mg of Levofloxacin, USP<br/>(5 mg/mL) in 5% dextrose. May contain Hydrochloric Acid, NF and/or Sodium<br/>Hydroxide, NF to adjust pH to 3.8-5.8.<br/>
                     <content styleCode="bold">USUAL ADULT DOSAGE: </content>See package insert. Recommended storage: at or below<br/>25ºC (77ºF); however, brief exposure up to 40ºC (104ºF) does not adversely affect the<br/>product. Protect from light. Avoid excessive heat and protect from freezing.<br/>
                     <content styleCode="bold">Single dose container.</content> Additives should not be added or infused through<br/>the same intravenous line. The overwrap is a moisture barrier. Do not remove<br/>unit from overwrap until ready to use. Use unit promptly when pouch is open.<br/>After removing the overwrap, check for minute leaks by squeezing container<br/>firmly. If leaks are found, discard unit as sterility may be impaired. <content styleCode="bold">Use only<br/>if solution is clear and container is undamaged. DISCARD UNUSED<br/>PORTION. Must not be used in series connections.</content>
                     <content styleCode="bold">
                        <br/>
                     </content>Rx Only<br/>NDC 0143-9722-01</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20141007"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>TO OPEN - TEAR AT NOTCH ONE UNIT LEVOFLOXACIN INJECTION in 5% Dextrose 250 mg in 50 mL 5% Dextrose (5 mg/mL) FOR INTRAVENOUS INFUSION INFUSE OVER 60 MINUTES LEAVE BAG IN OVERWRAP UNTIL USE. PHARMACIST: Dispense the accompanying Medication Guide to each patient. Each 50 mL contains a dilute solution equivalent of 250 mg of Levofloxacin, USP (5 mg/mL) in 5% dextrose. May contain Hydrochloric Acid, NF and/or Sodium Hydroxide, NF to adjust pH to 3.8-5.8. USUAL ADULT DOSAGE: See package insert. Recommended storage: at or below 25ºC (77ºF); however, brief exposure up to 40ºC (104ºF) does not adversely affect the product. Protect from light. Avoid excessive heat and protect from freezing. Single dose container. Additives should not be added or infused through the same intravenous line. The overwrap is a moisture barrier. Do not remove unit from overwrap until ready to use. Use unit promptly when pouch is open. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired. Use only if solution is clear and container is undamaged. DISCARD UNUSED PORTION. Must not be used in series connections. Rx Only NDC 0143-9722-01</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levofloxacin-injection-in-5-percent-dextrose-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4c359d83-db0f-4707-ae17-9d8d7a5e2a25">
               <id root="40e5be5a-3801-4b81-987a-16312d5df699"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>TO OPEN - TEAR AT NOTCH<br/>ONE UNIT<br/>
                     <content styleCode="bold">LEVOFLOXACIN INJECTION<br/>in 5% Dextrose</content>
                     <br/>
                     <content styleCode="bold">500 mg in 100 mL 5% Dextrose (5 mg/mL)<br/>FOR INTRAVENOUS INFUSION<br/>INFUSE OVER 60 MINUTES<br/>LEAVE BAG IN OVERWRAP UNTIL USE.<br/>PHARMACIST: Dispense the accompanying<br/>Medication Guide to each patient.<br/>
                     </content>Each 100 mL contains a dilute solution equivalent of 500 mg of Levofloxacin, USP (5 mg/mL) in<br/>5% dextrose. May contain Hydrochloric Acid, NF and/or Sodium Hydroxide, NF to adjust pH to<br/>3.8-5.8.<br/>
                     <content styleCode="bold">USUAL ADULT DOSAGE: </content>See package insert. Recommended storage: at or below 25ºC (77ºF);<br/>however, brief exposure up to 40ºC (104ºF) does not adversely affect the product. Protect from<br/>light. Avoid excessive heat and protect from freezing.<br/>
                     <content styleCode="bold">Single dose container.</content> Additives should not be added or infused through the same intravenous<br/>line. The overwrap is a moisture barrier. Do not remove unit from overwrap until ready to use.<br/>Use unit promptly when pouch is open. After removing the overwrap, check for minute leaks by<br/>squeezing container firmly. If leaks are found, discard unit as sterility may be impaired. <content styleCode="bold">Use only<br/>if solution is clear and container is undamaged. DISCARD UNUSED PORTION. Must not<br/>be used in series connections.</content>
                     <content styleCode="bold">
                        <br/>
                     </content>Rx Only<br/>NDC 0143-9721-01</paragraph>
                  <paragraph> <renderMultiMedia referencedObject="MM5"/>
                  </paragraph>
               </text>
               <effectiveTime value="20141007"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>TO OPEN - TEAR AT NOTCH ONE UNIT LEVOFLOXACIN INJECTION in 5% Dextrose 500 mg in 100 mL 5% Dextrose (5 mg/mL) FOR INTRAVENOUS INFUSION INFUSE OVER 60 MINUTES LEAVE BAG IN OVERWRAP UNTIL USE. PHARMACIST: Dispense the accompanying Medication Guide to each patient. Each 100 mL contains a dilute solution equivalent of 500 mg of Levofloxacin, USP (5 mg/mL) in 5% dextrose. May contain Hydrochloric Acid, NF and/or Sodium Hydroxide, NF to adjust pH to 3.8-5.8. USUAL ADULT DOSAGE: See package insert. Recommended storage: at or below 25ºC (77ºF); however, brief exposure up to 40ºC (104ºF) does not adversely affect the product. Protect from light. Avoid excessive heat and protect from freezing. Single dose container. Additives should not be added or infused through the same intravenous line. The overwrap is a moisture barrier. Do not remove unit from overwrap until ready to use. Use unit promptly when pouch is open. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired. Use only if solution is clear and container is undamaged. DISCARD UNUSED PORTION. Must not be used in series connections. Rx Only NDC 0143-9721-01</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levofloxacin-injection-in-5-percent-dextrose-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5bbfb114-5251-45c8-9d66-e11c4e8ff6ed">
               <id root="a6a0aacd-ae1d-4b52-88c1-1f64b375c859"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>TO OPEN - TEAR AT NOTCH<br/>ONE UNIT<br/>
                     <content styleCode="bold">LEVOFLOXACIN INJECTION<br/>in 5% Dextrose</content>
                     <br/>
                     <content styleCode="bold">750 mg in 150 mL 5% Dextrose (5 mg/mL)<br/>FOR INTRAVENOUS INFUSION<br/>INFUSE OVER 90 MINUTES<br/>LEAVE BAG IN OVERWRAP UNTIL USE.<br/>PHARMACIST: Dispense the accompanying<br/>Medication Guide to each patient.<br/>
                     </content>Each 150 mL contains a dilute solution equivalent of 750 mg<br/> of Levofloxacin, USP (5 mg/mL) in 5% dextrose. May contain<br/> Hydrochloric Acid, NF and/or Sodium Hydroxide, NF to adjust<br/> pH to 3.8-5.8.<br/>
                     <content styleCode="bold">USUAL ADULT DOSAGE: </content>See package insert. Recommended<br/> storage: at or below 25ºC (77ºF); however, brief exposure up to<br/> 40ºC (104ºF) does not adversely affect the product. Protect from<br/>light. Avoid excessive heat and protect from freezing.<br/>
                     <content styleCode="bold">Single dose container.</content> Additives should not be added or<br/> infused through the same intravenous line. The overwrap is<br/> a moisture barrier. Do not remove unit from overwrap until<br/> ready to use. Use unit promptly when pouch is open. After<br/> removing the overwrap, check for minute leaks by squeezing<br/> container firmly. If leaks are found, discard unit as sterility may<br/> be impaired. <content styleCode="bold">Use only if solution is clear and container is<br/> undamaged. DISCARD UNUSED PORTION. Must not be<br/> used in series connections.</content>
                     <content styleCode="bold">
                        <br/>
                     </content>Rx Only<br/>NDC 0143-9720-01</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20141007"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>TO OPEN - TEAR AT NOTCH ONE UNIT LEVOFLOXACIN INJECTION in 5% Dextrose 750 mg in 150 mL 5% Dextrose (5 mg/mL) FOR INTRAVENOUS INFUSION INFUSE OVER 90 MINUTES LEAVE BAG IN OVERWRAP UNTIL USE. PHARMACIST: Dispense the accompanying Medication Guide to each patient. Each 150 mL contains a dilute solution equivalent of 750 mg of Levofloxacin, USP (5 mg/mL) in 5% dextrose. May contain Hydrochloric Acid, NF and/or Sodium Hydroxide, NF to adjust pH to 3.8-5.8. USUAL ADULT DOSAGE: See package insert. Recommended storage: at or below 25ºC (77ºF); however, brief exposure up to 40ºC (104ºF) does not adversely affect the product. Protect from light. Avoid excessive heat and protect from freezing. Single dose container. Additives should not be added or infused through the same intravenous line. The overwrap is a moisture barrier. Do not remove unit from overwrap until ready to use. Use unit promptly when pouch is open. After removing the overwrap, check for minute leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired. Use only if solution is clear and container is undamaged. DISCARD UNUSED PORTION. Must not be used in series connections. Rx Only NDC 0143-9720-01</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levofloxacin-injection-in-5-percent-dextrose-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>